<SEC-DOCUMENT>0001104659-25-084879.txt : 20250828
<SEC-HEADER>0001104659-25-084879.hdr.sgml : 20250828
<ACCEPTANCE-DATETIME>20250828173007
ACCESSION NUMBER:		0001104659-25-084879
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250828
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250828
DATE AS OF CHANGE:		20250828

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Journey Medical Corp
		CENTRAL INDEX KEY:			0001867066
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				471879539
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41063
		FILM NUMBER:		251274896

	BUSINESS ADDRESS:	
		STREET 1:		9237 E VIA DE VENTURA BLVD., SUITE 105
		CITY:			SCOTTSDALE
		STATE:			AZ
		ZIP:			85258
		BUSINESS PHONE:		480-434-6670

	MAIL ADDRESS:	
		STREET 1:		9237 E VIA DE VENTURA BLVD., SUITE 105
		CITY:			SCOTTSDALE
		STATE:			AZ
		ZIP:			85258
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2524202d2_8kseq1.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:DERM="http://journeymedicalcorp.com/20250828">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_DERM_journeymedicalcorp.com_20250828 -->
<!-- Field: Set; Name: xdx; ID: xdx_047_20250828_20250828 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001867066 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-08-28" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-08-28" id="Fact000004" name="dei:EntityCentralIndexKey">0001867066</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="derm-20250828.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-08-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001867066</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-28</xbrli:startDate>
        <xbrli:endDate>2025-08-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90B_edei--DocumentType_c20250828__20250828_zhKlyK3bAApg"><ix:nonNumeric contextRef="AsOf2025-08-28" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported): <b><span id="xdx_901_edei--DocumentPeriodEndDate_c20250828__20250828_zT5q5n3vnUof"><ix:nonNumeric contextRef="AsOf2025-08-28" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">August 28, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityRegistrantName_c20250828__20250828_zzq1Z0APhxJh"><ix:nonNumeric contextRef="AsOf2025-08-28" id="Fact000011" name="dei:EntityRegistrantName">Journey Medical Corporation</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; width: 32%; font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20250828__20250828_zNn1YseXC6q5"><ix:nonNumeric contextRef="AsOf2025-08-28" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; width: 2%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 32%; font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90E_edei--EntityFileNumber_c20250828__20250828_z8vUi7EQqDw8"><ix:nonNumeric contextRef="AsOf2025-08-28" id="Fact000013" name="dei:EntityFileNumber">001-41063</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; width: 2%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 32%; font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20250828__20250828_zsHOHFKiU2b9"><ix:nonNumeric contextRef="AsOf2025-08-28" id="Fact000014" name="dei:EntityTaxIdentificationNumber">47-1879539</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: center">(State or Other Jurisdiction<br/> of Incorporation)</td><td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center">(Commission File Number)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-style: normal; font-weight: normal">(IRS
    Employer Identification No.)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20250828__20250828_zQx26E7bscNb"><ix:nonNumeric contextRef="AsOf2025-08-28" id="Fact000015" name="dei:EntityAddressAddressLine1">9237 E Via de Ventura Blvd.</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressAddressLine2_c20250828__20250828_zACUHW2HvKSb"><ix:nonNumeric contextRef="AsOf2025-08-28" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 105</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_907_edei--EntityAddressCityOrTown_c20250828__20250828_zpG68Sp2VJTf"><ix:nonNumeric contextRef="AsOf2025-08-28" id="Fact000017" name="dei:EntityAddressCityOrTown">Scottsdale</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20250828__20250828_zY5VCVlJ4Xo2"><ix:nonNumeric contextRef="AsOf2025-08-28" id="Fact000018" name="dei:EntityAddressStateOrProvince">AZ</ix:nonNumeric></span> <span id="xdx_900_edei--EntityAddressPostalZipCode_c20250828__20250828_zrK7SljMR6ki"><ix:nonNumeric contextRef="AsOf2025-08-28" id="Fact000019" name="dei:EntityAddressPostalZipCode">85258</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of Principal Executive Offices)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <b><span>(<span id="xdx_901_edei--CityAreaCode_c20250828__20250828_zEpoEPwwL3q1"><ix:nonNumeric contextRef="AsOf2025-08-28" id="Fact000020" name="dei:CityAreaCode">480</ix:nonNumeric></span>) <span id="xdx_90F_edei--LocalPhoneNumber_c20250828__20250828_zCEBNuHUaTMl"><ix:nonNumeric contextRef="AsOf2025-08-28" id="Fact000021" name="dei:LocalPhoneNumber">434-6670</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span id="xdx_90D_edei--WrittenCommunications_c20250828__20250828_z4ZwfE5G0Y28" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-08-28" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Written communications pursuant to Rule 425 under the Securities
Act.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span id="xdx_90D_edei--SolicitingMaterial_c20250828__20250828_zsMF2JVUtXue" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-08-28" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange
Act.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span id="xdx_90E_edei--PreCommencementTenderOffer_c20250828__20250828_z8rK1Ucmlqpd" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-08-28" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2b under
the Exchange Act.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span id="xdx_90B_edei--PreCommencementIssuerTenderOffer_c20250828__20250828_zezgDiV3aC02" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-08-28" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin: 0">Securities registered pursuant to Section 12(b) of the Act:</p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: Black 1pt solid; padding: 2pt 5.4pt; vertical-align: bottom; width: 38%; text-align: center"><span style="font-size: 10pt">Title
    of each class</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; vertical-align: bottom; width: 22%; text-align: center"><span style="font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; width: 40%; text-align: center"><span style="font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt 5.4pt"><span style="font-size: 10pt"><span id="xdx_90C_edei--Security12bTitle_c20250828__20250828_zIFNFfowTEc7"><ix:nonNumeric contextRef="AsOf2025-08-28" id="Fact000026" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_edei--TradingSymbol_c20250828__20250828_zxoKJav6wY37"><ix:nonNumeric contextRef="AsOf2025-08-28" id="Fact000027" name="dei:TradingSymbol">DERM</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_900_edei--SecurityExchangeName_c20250828__20250828_zMd0ZTm0h8S4"><ix:nonNumeric contextRef="AsOf2025-08-28" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). &#160;&#160;<span style="font-family: Wingdings"><span id="xdx_908_edei--EntityEmergingGrowthCompany_c20250828__20250828_zonBSHbXt0vb"><ix:nonNumeric contextRef="AsOf2025-08-28" format="ixt:booleantrue" id="Fact000029" name="dei:EntityEmergingGrowthCompany">x</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings"><span id="xdx_90C_edei--EntityExTransitionPeriod_c20250828__20250828_zUZq9WnFP5ol"><ix:nonNumeric contextRef="AsOf2025-08-28" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityExTransitionPeriod">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Wingdings; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Wingdings; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 1.01.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry into a Material Definitive Agreement.</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 28, 2025, Journey Medical Corporation
(the &#8220;Company&#8221;) entered into an At Market Issuance Sales Agreement (the &#8220;Sales Agreement&#8221;) with B. Riley Securities,
Inc. (&#8220;B. Riley&#8221;) and Lake Street Capital Markets, LLC (&#8220;Lake Street&#8221;), as sales agents or principals (each of
B. Riley and Lake Street, an &#8220;Agent,&#8221; and together, the &#8220;Agents&#8221;), under which the Company may offer and sell,
from time to time at its sole discretion, 3,750,000 shares of its common stock, par value $0.0001 per share (the &#8220;Shares&#8221;),
through or to the Agents. The issuance and sale, if any, of Shares by the Company under the Sales Agreement will be made pursuant to the
Company&#8217;s registration statement on Form S-3 (File No. 333-269079), which was originally filed with the Securities and Exchange
Commission (the &#8220;SEC&#8221;) on December 30, 2022 and declared effective on January 26, 2023, and the prospectus supplement, dated
and filed with the SEC pursuant to&#160;Rule 424(b) under the&#160;Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;)
on August 28, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Sales Agreement, the Agents may sell
Shares by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415(a)(4) under the&#160;Securities
Act. The Agents will use commercially reasonable efforts to sell the Shares from time to time, based upon instructions from the Company
(including any price, time or size limits or other customary parameters or conditions the Company may impose). The&#160;Sales Agreement&#160;contains
customary representations, warranties, and agreements of the Company and the Agents.&#160;The Company will pay each Agent a commission
of 3.0% of the gross proceeds from the sales of Shares sold through such Agent under the Sales Agreement and has provided the Agents with
customary indemnification and contribution rights. The Company will also reimburse the Agents for certain expenses incurred in connection
with the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is not obligated to make any sales
of Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the
sale of all Shares subject to the Sales Agreement or (ii) the termination of the Sales Agreement in accordance with its terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the Sales Agreement
does not purport to be complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which
is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. A copy of the legal opinion of
Troutman Pepper Locke LLP relating to the legality of the issuance of the Shares in the offering is attached as Exhibit 5.1 hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report on Form 8-K shall not constitute
an offer to sell or the solicitation of an offer to buy any Shares, nor shall there be any sale of such Shares in any state in which such
offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item&#8239;1.02 Termination of a Material Definitive
Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously disclosed, on December 30, 2022 the Company entered into that certain At Market Issuance Sales Agreement (the &#8220;Original
Sales Agreement&#8221;) with B. Riley pursuant to which the Company could offer and sell, from time to time at its sole discretion, 4,900,000
shares of its common stock, through or to B. Riley</span>, in sales deemed to be an &#8220;at the market offering&#8221; as defined in
Rule 415(a)(4) under the Securities Act. Effective as of August 28, 2025, the Company terminated the Original Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the termination of the Original Sales
Agreement, the Company may not offer or sell any additional shares of common stock under the Original Sales Agreement. From December 30,
2022 to August 28, 2025, the Company sold 4,121,318 shares of common stock pursuant to the Original Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the Original Sales
Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Original Sales Agreement,
a copy of which was filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 3, 2023, and
incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01. Financial Statements and Exhibits. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibits are furnished herewith:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
    Number</b></span></td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2524202d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2524202d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Troutman Pepper
    Locke LLP.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2524202d2_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: top"><a href="tm2524202d2_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At Market Issuance Sales
    Agreement, dated as of August 28, 2025, by and among Journey Medical Corporation, B. Riley Securities, Inc. and Lake Street Capital
    Markets, LLC.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2524202d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2524202d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Troutman Pepper
    Locke LLP (contained in Exhibit 5.1).</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive
    Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Journey Medical Corporation</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 28, 2025</span></td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 46%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right"/>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Claude Maraoui</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claude Maraoui</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwjAQhU/QOwxZF02DLuxOixaxihQRt8FOJdhmyiT+HclbGlvEYWAY3vveEyIWOa1MgwynRVnAAduu0R6hxBoZ7RmDI1tvUgi3xItxnrX1/fsDMwoMBmY6UkoHobfejcMqBTkdy2SsJiBnaTKD+VZEXz0jW5sKrTe6AW0r2DN1bNBrfg0JB/0kS+2rrzoiO0M2hWQkB/kNSiYKdnTXD+Krg6LIRBT3E4mc6dYF1/Lp0X5JWDbYhjo30P+NPgB5SoI= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>tm2524202d2_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><P STYLE="margin-top: 0; margin-bottom: 0">Troutman Pepper Locke LLP</P>
                         <P STYLE="margin-top: 0; margin-bottom: 0">301 S. College Street, 34th Floor</P>
                         <P STYLE="margin-top: 0; margin-bottom: 0">Charlotte, NC 28202</P>
                         <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                         <P STYLE="margin-top: 0; margin-bottom: 0">troutman.com</P></TD>
  <TD STYLE="text-align: right; width: 50%"><IMG SRC="tm2524202d2_ex5-1img001.jpg" ALT=""></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: right"></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August 28, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Journey Medical Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9237 E Via de Ventura Blvd., Suite 105</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scottsdale, AZ 85258</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Re:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Journey
Medical Corporation At Market Issuance Sales Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as counsel to
Journey Medical Corporation, a Delaware corporation (the &#8220;<B><I>Company</I></B>&#8221;), in connection with the prospectus supplement,
dated August 28, 2025 (the &#8220;<B><I>Prospectus Supplement</I></B>&#8221;), relating to the offer and sale by the Company from time
to time of up to 3,750,000 shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;<B><I>Shares</I></B>&#8221;),
pursuant to an At Market Issuance Sales Agreement, dated August 28, 2025 (the &#8220;<B>Sales Agreement</B>&#8221;), among the Company,
B. Riley Securities, Inc. and Lake Street Capital Markets, LLC, as agents, included in the Company&#8217;s Registration Statement on Form
S-3 (File No. 333-269079) (the &#8220;<B><I>Registration Statement</I></B>&#8221;) filed by the Company on December 30, 2022 with the
Securities and Exchange Commission (the &#8220;<B><I>SEC</I></B>&#8221;) and declared effective by the SEC on January 26, 2023 under the
Securities Act of 1933, as amended (the &#8220;<B><I>Securities Act</I></B>&#8221;). The base prospectus included in the Registration
Statement is referred to herein as the &#8220;<B><I>Prospectus</I></B>.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion letter is being
furnished in accordance with the requirements of Item 16 of Form S-3 and Item 601(b)(5)(i) of Regulation S-K promulgated under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have reviewed the corporate
proceedings taken by the Company with respect to the registration of the offer and sale of the Shares. We have also examined and relied
upon originals or copies of such corporate records, documents, agreements or other instruments of the Company, and such certificates and
records of public officials, and such other papers, as we have deemed necessary or appropriate in connection herewith. As to all matters
of fact, we have relied entirely upon certificates of officers of the Company, and have assumed, without independent inquiry, the accuracy
of those certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In rendering this opinion,
we have assumed: the genuineness and authenticity of all signatures on original documents; the legal capacity of all natural persons;
the authenticity of all documents submitted to us as originals; the conformity to originals of all documents submitted to us as certified
or photocopies; the accuracy and completeness of all documents and records reviewed by us; the accuracy, completeness and authenticity
of certificates issued by any governmental official, office or agency and the absence of change in the information contained therein from
the effective date of any such certificate; and the due authorization, execution and delivery of all documents where authorization, execution
and delivery are prerequisites to the effectiveness of such documents, except we make no such assumption as to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the
limitations set forth herein, we have made such examination of law as we have deemed necessary for the purposes of expressing the
opinions set forth in this letter. We express no opinion herein as to the law of any state or jurisdiction other than the General
Corporation Law of the State of Delaware, as currently in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><P STYLE="margin-top: 0; margin-bottom: 0">August 28, 2025</P>
                         <P STYLE="margin-top: 0; margin-bottom: 0">Page 2</P></TD>
  <TD STYLE="text-align: right; width: 50%"><IMG SRC="tm2524202d2_ex5-1img001.jpg" ALT=""></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: right"></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on and subject to the
foregoing and the exclusions, qualifications, limitations and other assumptions set forth in this opinion letter, we are of the opinion
that when (i) the Shares have been issued and sold as contemplated by the Registration Statement, the Prospectus and the Prospectus Supplement,
(ii) the Company has received the consideration provided for in the Sales Agreement, and (iii) such consideration per share is not less
than the amount specified in the proceedings of the Company&#8217;s board of directors approving the Sales Agreement, such Shares will
be validly issued, fully paid and non-assessable.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In rendering this opinion,
we have assumed that the resolutions of the board of directors (or a duly authorized committee thereof) of the Company authorizing the
Company to issue and deliver and sell the Shares pursuant to the Sales Agreement will be in full force and effect at all times at which
the Shares are issued and delivered or sold by the Company, and the Company will take no action inconsistent with such resolutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion letter is given
as of the date hereof, and we assume no obligation to supplement this opinion if any applicable law changes after the date hereof or if
we become aware of any facts or circumstances that may change the opinions expressed herein after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to the filing
of this opinion as Exhibit 5.1 to the Current Report on Form 8-K, dated the date hereof, filed by the Company and incorporated by reference
into the Registration Statement and to the reference to this firm under the heading &#8220;Legal Matters&#8221; in the Prospectus Supplement.
In rendering this opinion and giving this consent, we do not admit that we are an &#8220;expert&#8221; within the meaning of the Securities
Act or the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; width: 50%">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Troutman Pepper Locke LLP</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt">Troutman Pepper Locke LLP</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>tm2524202d2_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Execution
Version</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JOURNEY
MEDICAL CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Stock&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(par
value $0.0001 per share)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>At
Market Issuance Sales Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0; text-indent: 389.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August&nbsp;28,
2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Riley Securities,&nbsp;Inc.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">299
Park Avenue, 21<SUP>st</SUP> Floor&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10171</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lake
Street Capital Markets, LLC&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">121
South 8th Street, Suite&nbsp;1000&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minneapolis,
MN 55402</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Journey
Medical Corporation, a Delaware corporation (the &#8220;<U>Company</U>&#8221;), confirms its agreement (this &#8220;<U>Agreement</U>&#8221;)
with B. Riley Securities,&nbsp;Inc. (&#8220;<U>B. Riley Securities</U>&#8221;) and Lake Street Capital Markets, LLC (&#8220;<U>Lake Street</U>&#8221;;
each of B. Riley Securities and Lake Street individually an &#8220;<U>Agent</U>&#8221; and collectively, the &#8220;<U>Agents</U>&#8221;)
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Issuance
and Sale of Shares</U>. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the
conditions set forth herein, it may issue and sell through or to the Agents, as sales agent or principal, shares (the &#8220;<U>Placement
Shares</U>&#8221;) of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;<U>Common Stock</U>&#8221;); <I>provided
however, </I>that in no event shall the Company issue or sell through the Agents such number of Placement Shares that (a)&nbsp;exceeds
the number of shares or dollar amount of Common Stock registered on the effective Registration Statement (as defined below) pursuant
to which the offering is being made or (b)&nbsp;exceeds the number of shares or dollar amount registered on the Prospectus Supplement
(as defined below) (the lesser of (a)&nbsp;or (b)&nbsp;the &#8220;<U>Maximum Amount</U>&#8221;) and <I>provided further, however,</I>
that in no event shall the aggregate number of Placement Shares sold pursuant to this Agreement exceed the number of authorized but unissued
shares of Common Stock. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the
limitations set forth in this <U>Section&nbsp;1</U> on the number of Placement Shares issued and sold under this Agreement shall be the
sole responsibility of the Company and that the Agents shall have no obligation in connection with such compliance. The issuance and
sale of Placement Shares through the Agents will be effected pursuant to the Registration Statement (as defined below), although nothing
in this Agreement shall be construed as requiring the Company to use the Registration Statement to issue any Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has filed, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules&nbsp;and regulations thereunder
(the &#8220;<U>Securities Act</U>&#8221;), with the Securities and Exchange Commission (the &#8220;<U>Commission</U>&#8221;), a registration
statement on Form&nbsp;S-3 (File No.&nbsp;333-269079), including a base prospectus, relating certain securities including the Placement
Shares to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will
file in accordance with the provisions of the Securities Exchange Act of 1934, as amended and the rules&nbsp;and regulations thereunder
(the &#8220;<U>Exchange Act</U>&#8221;). The Company has prepared a prospectus supplement to the base prospectus included as part of
such registration statement specifically relating to the Placement Shares (the &#8220;<U>Prospectus Supplement</U>&#8221;). The Company
will furnish to the Agents, for use by the Agents, copies of the base prospectus included as part of such registration statement, as
supplemented by the Prospectus Supplement, as the same may be replaced or supplemented, relating to the Placement Shares. Except where
the context otherwise requires, such registration statement, and any post-effective amendment thereto, including all documents filed
as part thereof or incorporated by reference therein, and including any information contained in a Prospectus (as defined below) subsequently
filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;under the Securities Act or deemed to be a part of such registration statement
pursuant to Rule&nbsp;430B of the Securities Act or any subsequent registration statement on Form&nbsp;S-3 filed pursuant to Rule&nbsp;415
under the Securities Act by the Company to cover any Placement Shares, is herein called the &#8220;<U>Registration Statement</U>.&#8221;
The base prospectus and the Prospectus Supplement, including all documents incorporated or deemed incorporated therein by reference to
the extent such information has not been superseded or modified in accordance with Rule&nbsp;412 under the Securities Act (as qualified
by Rule&nbsp;430B(g)&nbsp;of the Securities Act), included in the Registration Statement, as it may be supplemented by any additional
prospectus supplement relating to the offer and sale of the Placement Shares, in the form in which such base prospectus, Prospectus Supplement
and/or any additional supplement thereto have most recently been filed by the Company with the Commission pursuant to Rule&nbsp;424(b)&nbsp;under
the Securities Act is herein called the &#8220;<U>Prospectus</U>.&#8221; Any reference herein to the Registration Statement, the Prospectus
or any amendment or supplement thereto shall be deemed to refer to and include the documents incorporated by reference therein, and any
reference herein to the terms &#8220;amend,&#8221; &#8220;amendment&#8221; or &#8220;supplement&#8221; with respect to the Registration
Statement or the Prospectus shall be deemed to refer to and include the filing after the execution hereof of any document with the Commission
incorporated by reference therein (the &#8220;<U>Incorporated Documents</U>&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Agreement, all references to the Registration Statement, the Prospectus or to any amendment or supplement thereto shall
be deemed to include the most recent copy filed with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval
System, or if applicable, the Interactive Data Electronic Application system when used by the Commission (collectively, &#8220;<U>EDGAR</U>&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Placements</U>.
Each time that the Company wishes to issue and sell Placement Shares hereunder (each, a &#8220;<U>Placement</U>&#8221;), it will notify
an Agent (the &#8220;<U>Designated Agent</U>&#8221;) by electronic mail (or other method mutually agreed to in writing by the parties)
of the number of Placement Shares, the time period during which sales are requested to be made, any limitation on the number of Placement
Shares that may be sold in any one day and any minimum price below which sales may not be made (a &#8220;<U>Placement Notice</U>&#8221;),
the form of which is attached hereto as <U>Schedule 1</U>. The Placement Notice shall originate from any of the individuals from the
Company set forth on <U>Schedule 3</U> (with a copy to each of the other individuals from the Company listed on such schedule), and shall
be addressed to each of the individuals from the Designated Agent set forth on <U>Schedule 3,</U> as such <U>Schedule 3</U> may be amended
from time to time. The Placement Notice shall be effective immediately upon receipt by the Designated Agent unless and until (i)&nbsp;the
Designated Agent declines to accept the terms contained therein for any reason, in its sole discretion, (ii)&nbsp;the entire amount of
the Placement Shares thereunder has been sold, (iii)&nbsp;the Company suspends or terminates the Placement Notice, which suspension and
termination rights may be exercised by the Company in its sole discretion, or (iv)&nbsp;this Agreement has been terminated under the
provisions of <U>Section&nbsp;13</U>. The amount of any discount, commission or other compensation to be paid by the Company to the Designated
Agent in connection with the sale of the Placement Shares shall be calculated in accordance with the terms set forth in <U>Schedule 2</U>.
It is expressly acknowledged and agreed that neither the Company nor the Designated Agent will have any obligation whatsoever with respect
to a Placement or any Placement Shares unless and until the Company delivers a Placement Notice to the Designated Agent and the Designated
Agent does not decline such Placement Notice pursuant to the terms set forth above, and then only upon the terms specified therein and
herein. In the event of a conflict between the terms of <U>Sections 2</U> or <U>3</U> of this Agreement and the terms of a Placement
Notice, the terms of the Placement Notice will control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Sale
of Placement Shares by the Agents</U>. Subject to the terms and conditions of this Agreement, for the period specified in a Placement
Notice, the Designated Agent will use its commercially reasonable efforts consistent with its normal trading and sales practices and
applicable state and federal laws, rules&nbsp;and regulations and the rules&nbsp;of The Nasdaq Stock Market LLC (the &#8220;<U>Exchange</U>&#8221;),
to sell the Placement Shares up to the amount specified in, and otherwise in accordance with the terms of, such Placement Notice. The
Designated Agent will provide written confirmation to the Company no later than the opening of the Trading Day (as defined below) immediately
following the Trading Day on which it has made sales of Placement Shares hereunder setting forth the number of Placement Shares sold
on such day, the compensation payable by the Company to the Designated Agent pursuant to <U>Section&nbsp;2</U> with respect to such sales,
and the Net Proceeds (as defined below) payable to the Company, with an itemization of the deductions made by the Designated Agent (as
set forth in <U>Section&nbsp;5(b))</U> from the gross proceeds that it receives from such sales. Subject to the terms of a Placement
Notice, the Designated Agent may sell Placement Shares by any method permitted by law deemed to be an &#8220;at the market offering&#8221;
as defined in Rule&nbsp;415 of the Securities Act. &#8220;<U>Trading Day</U>&#8221; means any day on which shares of Common Stock are
purchased and sold on the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Suspension
of Sales</U>. The Company or the Designated Agent may, upon notice to the other party in writing (including by email correspondence to
each of the individuals of the other party set forth on <U>Schedule 3</U>, if receipt of such correspondence is actually acknowledged
by any of the individuals to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by verifiable
email correspondence to each of the individuals of the other party set forth on <U>Schedule </U>3), suspend any sale of Placement Shares
pursuant to a Placement Notice delivered to such Agent (a &#8220;<U>Suspension</U>&#8221;); <I>provided, however</I>, that such suspension
shall not affect or impair any party&#8217;s obligations with respect to any Placement Shares sold hereunder prior to the receipt of
such notice. While a Suspension is in effect, any obligation under <U>Sections 7(l)</U>, <U>7(m)</U>, and <U>7(n)</U>&nbsp;with respect
to the delivery of certificates, opinions, or comfort letters to the Agents, shall be waived. Each of the parties agrees that no such
notice under this <U>Section&nbsp;4</U> shall be effective against any other party unless it is made to one of the individuals named
on <U>Schedule 3</U> hereto, as such Schedule may be amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Sale
and Delivery to the Designated Agent; Settlement</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<U>Sale
of Placement Shares</U>. On the basis of the representations and warranties herein contained and subject to the terms and conditions
herein set forth, upon the Designated Agent&#8217;s acceptance of the terms of a Placement Notice, and unless the sale of the Placement
Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms of this Agreement, the Designated
Agent, for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading
and sales practices and applicable state and federal laws, rules&nbsp;and regulations and the rules&nbsp;of the Exchange to sell such
Placement Shares up to the amount specified in, and otherwise in accordance with the terms of, such Placement Notice. The Company acknowledges
and agrees that (i)&nbsp;there can be no assurance that the Designated Agent will be successful in selling Placement Shares, (ii)&nbsp;the
Designated Agent will incur no liability or obligation to the Company or any other person or entity if it does not sell Placement Shares
for any reason other than a failure by the Designated Agent to use its commercially reasonable efforts consistent with its normal trading
and sales practices and applicable state and federal laws, rules&nbsp;and regulations and the rules&nbsp;of the Exchange to sell such
Placement Shares as required under this Agreement and (iii)&nbsp;the Designated Agent shall be under no obligation to purchase Placement
Shares on a principal basis pursuant to this Agreement, except as otherwise agreed by the Designated Agent and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<U>Settlement
of Placement Shares</U>. Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement Shares will
occur on the first&nbsp;(1<SUP>st</SUP>) Trading Day (or such earlier day as is industry practice for regular-way trading) following
the date on which such sales are made (each, a &#8220;<U>Settlement Date</U>&#8221;). The Designated Agent shall notify the Company of
each sale of Placement Shares no later than opening day following the Trading Day that the Designated Agent sold Placement Shares. The
amount of proceeds to be delivered to the Company on a Settlement Date against receipt of the Placement Shares sold (the &#8220;<U>Net
Proceeds</U>&#8221;) will be equal to the aggregate sales price received by the Designated Agent, after deduction for (i)&nbsp;the Designated
Agent&#8217;s commission, discount or other compensation for such sales payable by the Company pursuant to Section&nbsp;2 hereof, and
(ii)&nbsp;any transaction fees imposed by any governmental or self-regulatory organization in respect of such sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Delivery
of Placement Shares</U>. On or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer
the Placement Shares being sold by crediting the Designated Agent&#8217;s or its designee&#8217;s account (provided the Designated Agent
shall have given the Company written notice of such designee and such designee&#8217;s account information at least one Trading Day prior
to the Settlement Date) at The Depository Trust Company through its Deposit and Withdrawal at Custodian System or by such other means
of delivery as may be mutually agreed upon by the parties hereto which in all cases shall be freely tradable, transferable, registered
shares in good deliverable form. On each Settlement Date, the Designated Agent will deliver the related Net Proceeds in same day funds
to an account designated by the Company on, or prior to, the Settlement Date. The Company agrees that if the Company, or its transfer
agent (if applicable), defaults in its obligation to deliver Placement Shares on a Settlement Date through no fault of the Designated
Agent, then in addition to and in no way limiting the rights and obligations set forth in <U>Section&nbsp;11(a)</U>&nbsp;hereto, it will
(i)&nbsp;hold the Designated Agent harmless against any loss, claim, damage, or reasonable, documented expense (including reasonable
and documented legal fees and expenses), as incurred, arising out of or in connection with such default by the Company or its transfer
agent (if applicable) and (ii)&nbsp;pay to the Designated Agent (without duplication) any commission, discount, or other compensation
to which it would otherwise have been entitled absent such default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<U>Limitations
on Offering Size</U>. Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares if, after giving
effect to the sale of such Placement Shares, the aggregate number of Placement Shares sold pursuant to this Agreement would exceed the
lesser of (A)&nbsp;together with all sales of Placement Shares under this Agreement, the Maximum Amount, (B)&nbsp;the amount available
for offer and sale under the then-currently effective Registration Statement and (C)&nbsp;the amount authorized from time to time to
be issued and sold under this Agreement by the Company&#8217;s board of directors, a duly authorized committee thereof or a duly authorized
executive committee, and notified to the Designated Agent in writing. Under no circumstances shall the Company cause or request the offer
or sale of any Placement Shares pursuant to this Agreement at a price lower than the minimum price authorized from time to time by the
Company&#8217;s board of directors, a duly authorized committee thereof or a duly authorized executive committee, and notified to the
Designated Agent in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Sales
Through Agents</U>. The Company agrees that any offer to sell, any solicitation of an offer to buy, or any sales of, Placement Shares
using a method deemed to be an &#8220;at the market offering&#8221; as defined in Rule&nbsp;415 of the Securities Act shall only be effected
by or through an Agent, and only a single Agent, on any single given date, and in no event shall the Company request that more than one
Agent sell Placement Shares on the same day; <I>provided</I>, <I>however</I> that (i)&nbsp;the foregoing limitation shall not apply to
(A)&nbsp;exercise of any option, warrant, right or any conversion privilege set forth in the instruction governing such securities, (B)&nbsp;sales
solely to employees, directors or security holders of the Company or its subsidiaries, or to a trustee or other person acquiring such
securities for the accounts of such person and (ii)&nbsp;such limitation shall not apply (A)&nbsp;on any day during which no sales are
made pursuant to this Agreement or (B)&nbsp;during a period in which the Company has notified the Agents that it will not sell Common
Stock under this Agreement and (1)&nbsp;no Placement Notice is pending or (2)&nbsp;after a Placement Notice has been withdrawn.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Representations
and Warranties of the Company</U>. Except as disclosed in the Registration Statement or Prospectus (including the Incorporated Documents),
the Company represents and warrants to, and agrees with each of the Agents that as of the date of this Agreement and as of each Applicable
Time (as defined below), unless such representation, warranty or agreement specifies a different date or time:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Registration
Statement and Prospectus</U>. The transactions contemplated by this Agreement meet the requirements for and comply with the conditions
for the use of Form&nbsp;S&#45;3 under the Securities Act. The Registration Statement has been filed with the Commission and has been
declared effective under the Securities Act. The Prospectus Supplement will name B. Riley Securities and Lake Street as the agents in
the section titled &#8220;Plan of Distribution.&#8221; The Company has not received, and has no notice of, any order of the Commission
preventing or suspending the use of the Registration Statement, or threatening or instituting proceedings for that purpose. The Registration
Statement and the offer and sale of Placement Shares as contemplated hereby meet the requirements of Rule&nbsp;415 under the Securities
Act and comply in all material respects with said Rule. Any statutes, regulations, contracts or other documents that are required to
be described in the Registration Statement or the Prospectus or to be filed as exhibits to the Registration Statement have been so described
or filed, as applicable. Copies of the Registration Statement, the Prospectus, and any such amendments or supplements and all documents
incorporated by reference therein that were filed with the Commission on or prior to the date of this Agreement have been delivered,
or are available through EDGAR, to the Agents and their counsel. The Company has not distributed and, prior to the later to occur of
each Settlement Date and completion of the distribution of the Placement Shares, will not distribute any offering material in connection
with the offering or sale of the Placement Shares other than the Registration Statement and the Prospectus and any Issuer Free Writing
Prospectus (as defined below) to which the Agents have consented, which consent will not be unreasonably withheld or delayed, or that
is required by applicable law or the listing maintenance requirements of the Exchange. The Common Stock is currently quoted on the Exchange
under the trading symbol &#8220;DERM.&#8221; The Company has not, in the 12&nbsp;months preceding the date hereof, received notice from
the Exchange to the effect that the Company is not in compliance with the listing or maintenance requirements of the Exchange. To the
Company&#8217;s knowledge, it is in compliance with all such listing and maintenance requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Misstatement or Omission</U>. At each Settlement Date, the Registration Statement and the Prospectus, as of such date, will conform in
all material respects with the requirements of the Securities Act. The Registration Statement, when it became or becomes effective, did
not, and will not, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
to make the statements therein not misleading. The Prospectus and any amendment and supplement thereto, on the date thereof and at each
Applicable Time (defined below), did not or will not include an untrue statement of a material fact or omit to state a material fact
necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. The documents incorporated
by reference in the Prospectus or any Prospectus Supplement did not, and any further documents filed and incorporated by reference therein
will not, when filed with the Commission, contain an untrue statement of a material fact or omit to state a material fact required to
be stated in such document or necessary to make the statements in such document, in light of the circumstances under which they were
made, not misleading. The foregoing shall not apply to statements in, or omissions from, any such document made in reliance upon, and
in conformity with, information furnished to the Company by an Agent specifically for use in the preparation thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Conformity
with Securities Act and Exchange Act</U>. The Registration Statement, the Prospectus, any Issuer Free Writing Prospectus or any amendment
or supplement thereto, and the Incorporated Documents, when such documents were or are filed with the Commission under the Securities
Act or the Exchange Act or became or become effective under the Securities Act, as the case may be, conformed or will conform in all
material respects with the requirements of the Securities Act and the Exchange Act, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Financial
Information</U>. The consolidated financial statements of the Company included or incorporated by reference in the Registration Statement
and the Prospectus, together with the related notes and schedules, present fairly, in all material respects, the consolidated financial
position of the Company and the Subsidiaries (as defined below) as of the dates indicated and the consolidated results of operations,
cash flows and changes in stockholders&#8217; equity of the Company and the Subsidiaries for the periods specified (subject, in the case
of unaudited statements, to normal year-end audit adjustments which will not be material, either individually or in the aggregate) and
have been prepared in compliance with the published requirements of the Securities Act and Exchange Act, as applicable, and in conformity
with generally accepted accounting principles in the United States (&#8220;<U>GAAP</U>&#8221;) applied on a consistent basis (except
(i)&nbsp;for such adjustments to accounting standards and practices as are noted therein and (ii)&nbsp;in the case of unaudited interim
statements, to the extent they may exclude footnotes or may be condensed or summary statements) during the periods involved; the other
financial and statistical data with respect to the Company and the Subsidiaries contained or incorporated by reference in the Registration
Statement and the Prospectus, are accurately and fairly presented and prepared on a basis consistent with the financial statements and
books and records of the Company; there are no financial statements (historical or pro forma) that are required to be included or incorporated
by reference in the Registration Statement, or the Prospectus that are not included or incorporated by reference as required; the Company
and the Subsidiaries do not have any material liabilities or obligations, direct or contingent (including any off balance sheet obligations),
not described in the Registration Statement, and the Prospectus which are required to be described in the Registration Statement or Prospectus;
and all disclosures contained or incorporated by reference in the Registration Statement and the Prospectus, if any, regarding &#8220;non-GAAP
financial measures&#8221; (as such term is defined by the rules&nbsp;and regulations of the Commission) comply in all material respects
with Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Securities Act, to the extent applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Conformity
with EDGAR Filing</U>. The Prospectus delivered to the Agents for use in connection with the sale of the Placement Shares pursuant to
this Agreement will be identical to the versions of the Prospectus created to be transmitted to the Commission for filing via EDGAR,
except to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Organization</U>. The Company and any subsidiary that is a significant subsidiary (as
such term is defined in Rule&nbsp;1-02 of Regulation S-X promulgated by the Commission) (each, a &#8220;<U>Subsidiary</U>,&#8221;
collectively, the &#8220;<U>Subsidiaries</U>&#8221;), are, and will be, duly organized, validly existing as a corporation and in
good standing under the laws of their respective jurisdictions of organization. The Company and the Subsidiaries are duly licensed
or qualified as a foreign corporation for transaction of business and in good standing under the laws of each other jurisdiction in
which their respective ownership or lease of property or the conduct of their respective businesses requires such license or
qualification, and have all corporate power and authority necessary to own or hold their respective properties and to conduct their
respective businesses as described in the Registration Statement and the Prospectus, except where the failure to be so qualified or
in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the
assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders&#8217; equity or
results of operations of the Company and the Subsidiaries taken as a whole, or prevent the consummation of the transactions
contemplated hereby (a &#8220;<U>Material Adverse Effect</U>&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Subsidiaries</U>.
The Company owns directly or indirectly, all of the equity interests of the Subsidiaries free and clear of any lien, charge, security
interest, encumbrance, right of first refusal or other restriction, and all the equity interests of the Subsidiaries are validly issued
and are fully paid, nonassessable and free of preemptive and similar rights. The Company does not own or control, directly or indirectly,
any corporation, association or other entity other than the subsidiaries listed in Exhibit&nbsp;21.1 to the Company&#8217;s Annual Report
on Form&nbsp;10-K for the most recently ended fiscal year and other than (i)&nbsp;those subsidiaries not required to be listed on Exhibit&nbsp;21.1
by Item 601 of Regulation S-K under the Exchange Act and (ii)&nbsp;those subsidiaries formed since the last day of the most recently
ended fiscal year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Violation or Default</U>. Neither the Company nor any Subsidiary is (i)&nbsp;in violation of its charter or by-laws or similar organizational
documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default,
in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement
or other similar agreement or instrument to which the Company or any Subsidiary is a party or by which the Company or any Subsidiary
is bound or to which any of the property or assets of the Company or any Subsidiary is subject; or (iii)&nbsp;in violation of any law
or statute or any judgment, order, rule&nbsp;or regulation of any court or arbitrator or governmental or regulatory authority, except,
in the case of each of clauses (ii)&nbsp;and (iii)&nbsp;above, for any such violation or default that would not, individually or in the
aggregate, have a Material Adverse Effect. To the Company&#8217;s knowledge, no other party under any material contract or other agreement
to which it or any Subsidiary is a party is in default in any respect thereunder where such default would have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Material Adverse Effect</U>. Since the date of the most recent financial statements of the Company included or incorporated by reference
in the Registration Statement and Prospectus, there has not been (i)&nbsp;any Material Adverse Effect, or any development that would
result in a Material Adverse Effect, (ii)&nbsp;any transaction which is material to the Company and the Subsidiaries taken as a whole,
(iii)&nbsp;any obligation or liability, direct or contingent (including any off-balance sheet obligations), incurred by the Company or
the Subsidiaries, which is material to the Company and the Subsidiaries taken as a whole, (iv)&nbsp;any material change in the capital
stock (other than (A)&nbsp;the grant of additional options, shares of restricted stock or restricted stock units under the Company&#8217;s
existing equity incentive plans and issuance of shares of Common Stock upon the exercise or vesting thereof, (B)&nbsp;changes in the
number of outstanding Common Stock of the Company due to the issuance of shares upon the exercise, vesting or conversion of securities
exercisable for, or convertible into, Common Stock outstanding on the date hereof, (C)&nbsp;as a result of the issuance of Placement
Shares, (D)&nbsp;any repurchases of capital stock of the Company, (E)&nbsp;as described in a proxy statement filed on Schedule 14A or
a Registration Statement on Form&nbsp;S-4, or (F)&nbsp;otherwise publicly announced) or outstanding long-term indebtedness of the Company
or the Subsidiaries or (v)&nbsp;any dividend or distribution of any kind declared, paid or made on the capital stock of the Company or
any Subsidiary (other than a distribution to the Company), other than in each case above in the ordinary course of business or as otherwise
disclosed in the Registration Statement or Prospectus (including any document incorporated by reference therein).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Capitalization</U>.
The issued and outstanding shares of capital stock of the Company have been validly issued, are fully paid and non-assessable and, other
than as disclosed in the Registration Statement or the Prospectus, are not subject to any preemptive rights, rights of first refusal
or similar rights. The Company has an authorized, issued and outstanding capitalization as set forth in the Registration Statement and
the Prospectus as of the dates referred to therein (other than (i)&nbsp;the grant of additional options under the Company&#8217;s existing
stock option plans, (ii)&nbsp;changes in the number of outstanding Common Stock of the Company due to the issuance of shares upon the
exercise or conversion of securities exercisable for, or convertible into, Common Stock outstanding on the date hereof, (iii)&nbsp;as
a result of the issuance of Placement Shares, or (iv)&nbsp;any repurchases of capital stock of the Company) and such authorized capital
stock conforms to the description thereof set forth in the Registration Statement and the Prospectus. The description of the Common Stock
in the Registration Statement and the Prospectus is complete and accurate in all material respects. Except as disclosed in or contemplated
by the Registration Statement or the Prospectus, the Company did not have outstanding any options to purchase, or any rights or warrants
to subscribe for, or any securities or obligations convertible into, or exchangeable for, or any contracts or commitments to issue or
sell, any shares of capital stock or other securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<U>S-3
Eligibility</U>. (i)&nbsp;At the time of filing the Registration Statement and (ii)&nbsp;at the time of the most recent amendment thereto
for the purposes of complying with Section&nbsp;10(a)(3)&nbsp;of the Securities Act (whether such amendment was by post-effective amendment,
incorporated report filed pursuant to Section&nbsp;13 or 15(d)&nbsp;of the Exchange Act or form of prospectus), the Company met the then-applicable
requirements for use of Form&nbsp;S-3 under the Securities Act, including, since the time of the most recent amendment thereto for the
purposes of complying with Section&nbsp;10(a)(3)&nbsp;of the Securities Act, compliance with General Instruction I.B.1 of Form&nbsp;S-3,
as applicable. The Company is not a shell company (as defined in Rule&nbsp;405 under the Securities Act) and has not been a shell company
for at least 12 calendar months previously and if it has been a shell company at any time previously, has filed current Form&nbsp;10
information (as defined in General Instruction I.B.6 of Form&nbsp;S-3) with the Commission at least 12 calendar months previously reflecting
its status as an entity that is not a shell company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Authorization;
Enforceability</U>. The Company has full legal right, power and authority to enter into this Agreement and perform the transactions contemplated
hereby. This Agreement has been duly authorized, executed and delivered by the Company and is a legal, valid and binding agreement of
the Company enforceable against the Company in accordance with its terms, except to the extent that (i)&nbsp;enforceability may be limited
by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#8217; rights generally and by general equitable
principles and (ii)&nbsp;the indemnification and contribution provisions of <U>Section&nbsp;11</U> hereof may be limited by federal or
state securities laws and public policy considerations in respect thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<U>Authorization
of Placement Shares</U>. The Placement Shares, when issued and delivered pursuant to the terms approved by the board of directors of
the Company or a duly authorized committee thereof, or a duly authorized executive committee, against payment therefor as provided herein,
will be duly and validly authorized and issued and fully paid and nonassessable, free and clear of any pledge, lien, encumbrance, security
interest or other claim (other than any pledge, lien, encumbrance, security interest or other claim arising from an act or omission of
an Agent or a purchaser), including any statutory or contractual preemptive rights, resale rights, rights of first refusal or other similar
rights, and will be registered pursuant to Section&nbsp;12 of the Exchange Act. The Placement Shares, when issued, will conform in all
material respects to the description thereof set forth in or incorporated into the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<U>No
Consents Required</U>. No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator or
any governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, and
the issuance and sale by the Company of the Placement Shares as contemplated hereby, except for such consents, approvals, authorizations,
orders and registrations or qualifications (i)&nbsp;as may be required under applicable state securities laws or by the by-laws and rules&nbsp;of
the Financial Industry Regulatory Authority (&#8220;<U>FINRA</U>&#8221;) or the Exchange, including any notices that may be required
by the Exchange, in connection with the sale of the Placement Shares by the Agents, (ii)&nbsp;as may be required under the Securities
Act and (iii)&nbsp;as have been previously obtained by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<U>No
Preferential Rights</U>. (i)&nbsp;No person, as such term is defined in Rule&nbsp;1-02 of Regulation S-X promulgated under the Securities
Act (each, a &#8220;<U>Person</U>&#8221;), has the right, contractual or otherwise, to cause the Company to issue or sell to such Person
any Common Stock or shares of any other capital stock or other securities of the Company (other than upon the exercise of options or
warrants to purchase Common Stock or upon the exercise of options that may be granted from time to time under the Company&#8217;s stock
option plan), (ii)&nbsp;no Person has any preemptive rights, rights of first refusal, or any other rights (whether pursuant to a &#8220;poison
pill&#8221; provision or otherwise) to purchase any Common Stock or shares of any other capital stock or other securities of the Company
from the Company which have not been duly waived with respect to the offering contemplated hereby, (iii)&nbsp;no Person has the right
to act as an underwriter or as a financial advisor to the Company in connection with the offer and sale of the Common Stock, and (iv)&nbsp;no
Person has the right, contractual or otherwise, to require the Company to register under the Securities Act the public sale or resale
of any Common Stock or shares of any other capital stock or other securities of the Company, or to include any such shares or other securities
in the Registration Statement or the offering contemplated thereby, whether as a result of the filing or effectiveness of the Registration
Statement or the sale of the Placement Shares as contemplated thereby or otherwise, except in each case for such rights as have been
waived on or prior to the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<U>Independent
Public Accountant</U>. KPMG LLP (the &#8220;<U>Accountant</U>&#8221;), whose report on the consolidated financial statements of the Company
is filed with the Commission as part of the Company&#8217;s most recent Annual Report on Form&nbsp;10-K filed with the Commission and
incorporated into the Registration Statement, are and, during the periods covered by their report, were independent public accountants
within the meaning of the Securities Act and the Public Company Accounting Oversight Board (United States). To the Company&#8217;s knowledge,
the Accountant is not in violation of the auditor independence requirements of the Sarbanes-Oxley Act of 2002 (the &#8220;<U>Sarbanes-Oxley
Act</U>&#8221;) with respect to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<U>Enforceability
of Agreements</U>. All agreements between the Company and third parties expressly referenced in the Prospectus, other than such agreements
that have expired by their terms or whose termination is disclosed in documents filed by the Company on EDGAR, are legal, valid and binding
obligations of the Company and, to the Company&#8217;s knowledge, enforceable in accordance with their respective terms, except to the
extent that (i)&nbsp;enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#8217;
rights generally and by general equitable principles and (ii)&nbsp;the indemnification provisions of certain agreements may be limited
by federal or state securities laws or public policy considerations in respect thereof, and except for any unenforceability that, individually
or in the aggregate, would not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Litigation</U>. To the Company&#8217;s knowledge, there are no legal, governmental or regulatory actions, suits or proceedings pending,
nor any legal, governmental or regulatory investigations, including any proceeding before the United States Food and Drug Administration
of the U.S. Department of Health and Human Services (the &#8220;<U>FDA</U>&#8221;) or comparable federal, state, local or foreign governmental
authorities (it being understood that the interaction between the Company and the FDA and such comparable governmental authorities relating
to the clinical development and product approval process shall not be deemed proceedings for purposes of this representation), to which
the Company or a Subsidiary is a party or to which any property of the Company or any Subsidiary is the subject that, individually or
in the aggregate, if determined adversely to the Company or any Subsidiary, would have a Material Adverse Effect or materially and adversely
affect the ability of the Company to perform its obligations under this Agreement; to the Company&#8217;s knowledge, no such actions,
suits or proceedings are threatened or contemplated in writing by any governmental or regulatory authority or threatened in writing by
others that, individually or in the aggregate, if determined adversely to the Company or any Subsidiary, would have a Material Adverse
Effect; and there are no current or pending legal, governmental or regulatory actions, suits, proceedings or, to the Company&#8217;s
knowledge, investigations that are required under the Securities Act to be described in the Prospectus that are not described in the
Prospectus (including any Incorporated Document). The Company is in compliance with all applicable federal, state, local and foreign
laws, regulations, orders and decrees governing its business as enforced by the FDA, or any other federal, state or foreign agencies
or bodies engaged in the regulation of medical devices, except where noncompliance would not, singularly or in the aggregate, reasonably
be expected to have a Material Adverse Effect. All preclinical and clinical studies conducted by or on behalf of the Company to support
clearance for commercialization of the Company&#8217;s products have been conducted by the Company, or to the Company&#8217;s knowledge
by third parties, in compliance with all applicable federal, state or foreign laws, rules, orders and regulations, except for such failure
or failures to be in compliance as would not reasonably be expected to have, singularly or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Licenses
and Permits</U>. The Company and the Subsidiaries possess or have obtained, all licenses, certificates, consents, orders, approvals,
permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or
foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct
of their respective businesses as currently conducted, as described in the Registration Statement and the Prospectus (the &#8220;<U>Permits</U>&#8221;),
except where the failure to possess, obtain or make the same would not, individually or in the aggregate, have a Material Adverse Effect.
Neither the Company nor any Subsidiary has received written notice of any proceeding relating to revocation or modification of any such
Permit or has any reason to believe that such Permit will not be renewed in the ordinary course, except where the failure to obtain any
such renewal would not, individually or in the aggregate, have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Material Defaults</U>. Neither the Company nor any Subsidiary has defaulted on any installment on indebtedness for borrowed money or
on any rental on one or more long-term leases, which defaults, individually or in the aggregate, would have a Material Adverse Effect.
The Company has not filed a report pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Exchange Act since the filing of its last
Annual Report on Form&nbsp;10-K, indicating that it (i)&nbsp;has failed to pay any dividend or sinking fund installment on preferred
stock or (ii)&nbsp;has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more long-term leases,
which defaults, individually or in the aggregate, would have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;<U>Certain Market Activities</U>. Neither the Company, nor any Subsidiary, nor, to the knowledge of the Company, any
of their respective directors, officers or controlling persons has taken, directly or indirectly, any action designed, or that has
constituted or would cause or result in, under the Exchange Act or otherwise, the stabilization or manipulation of the price of any
security of the Company to facilitate the sale or resale of the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Broker/Dealer
Relationships</U>. Neither the Company nor any Subsidiary or any related entities (i)&nbsp;is required to register as a &#8220;broker&#8221;
or &#8220;dealer&#8221; in accordance with the provisions of the Exchange Act or (ii)&nbsp;directly or indirectly through one or more
intermediaries, controls or is a &#8220;person associated with a member&#8221; or &#8220;associated person of a member&#8221; (within
the meaning set forth in the FINRA Manual).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">w.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Reliance</U>. The Company has not relied upon any Agent or legal counsel for the Agents for any legal, tax or accounting advice in connection
with the offering and sale of the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">x.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Taxes</U>.
The Company and the Subsidiaries have filed all federal, state, local and foreign tax returns which have been required to be filed and
paid all taxes shown thereon through the date hereof, to the extent that such taxes have become due and are not being contested in good
faith, except where the failure to do so would not have a Material Adverse Effect. Except as otherwise disclosed in or contemplated by
the Registration Statement or the Prospectus, no tax deficiency has been determined adversely to the Company or any Subsidiary which
has had, or would have, individually or in the aggregate, a Material Adverse Effect. The Company has no knowledge of any federal, state
or other governmental tax deficiency, penalty or assessment which has been or might be asserted or threatened against it which would
have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">y.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Title
to Real and Personal Property.</U> The Company and the Subsidiaries have good and valid title in fee simple to all items of real property
and good and valid title to all personal property described in the Registration Statement or Prospectus as being owned by them that are
material to the businesses of the Company or such Subsidiary, in each case free and clear of all liens, encumbrances and claims, except
those that (i)&nbsp;do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries
or (ii)&nbsp;would not, individually or in the aggregate, have a Material Adverse Effect. Any real property described in the Registration
Statement or Prospectus as being leased by the Company and the Subsidiaries is held by them under valid, existing and enforceable leases,
except those that (A)&nbsp;do not materially interfere with the use made or proposed to be made of such property by the Company or the
Subsidiaries or (B)&nbsp;would not, individually or in the aggregate, have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">z.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Intellectual
Property.</U> The Company and the Subsidiaries own or possess adequate enforceable rights to use all patents, patent applications, trademarks
(both registered and unregistered), trade names, trademark registrations, service marks, service mark registrations,&nbsp;Internet domain
name registrations, copyrights, copyright registrations, licenses and know-how (including trade secrets and other unpatented and/or unpatentable
proprietary or confidential information, systems or procedures) (collectively, the &#8220;<U>Intellectual Property</U>&#8221;), necessary
for the conduct of their respective businesses as conducted as of the date hereof, except to the extent that the failure to own or possess
adequate rights to use such Intellectual Property would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect. The Company and the Subsidiaries have not received any written notice of any claim of infringement or conflict which
asserted Intellectual Property rights of others, which infringement or conflict, if the subject of an unfavorable decision, would result
in a Material Adverse Effect. There are no pending, or to the Company&#8217;s knowledge threatened, judicial proceedings or interference
proceedings challenging the Company&#8217;s or any Subsidiary&#8217;s rights in or to or the validity of the scope of any of the Company&#8217;s
or its Subsidiaries&#8217; patents, patent applications or proprietary information. No other entity or individual has any right or claim
in any of the Company&#8217;s or any of its Subsidiary&#8217;s patents, patent applications or any patent to be issued therefrom by virtue
of any contract, license or other agreement entered into between such entity or individual and the Company or any Subsidiary or by any
non-contractual obligation, other than by written licenses granted by the Company or any Subsidiary. The Company has not received any
written notice of any claim challenging the rights of the Company or its Subsidiaries in or to any Intellectual Property owned, licensed
or optioned by the Company or any Subsidiary which claim, if the subject of an unfavorable decision, would result in a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">aa.&#9;&#8239;&#8239;&#8239;&#8239;&nbsp;<U>Compliance
with Applicable Laws</U>. The Company and the subsidiaries: (A)&nbsp;are and at all times have been in material compliance with all statutes,
rules&nbsp;and regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution,
marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured
or distributed by the Company or the subsidiaries (&#8220;<U>Applicable Laws</U>&#8221;), (b)&nbsp;have not received any Form&nbsp;483
from the FDA, notice of adverse finding, warning letter, or other written correspondence or notice from the FDA, the European Medicines
Agency (the &#8220;<U>EMA</U>&#8221;), or any other federal, state, local or foreign governmental or regulatory authority alleging or
asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits
and supplements or amendments thereto required by any such Applicable Laws (&#8220;<U>Authorizations</U>&#8221;), which would, individually
or in the aggregate, result in a Material Adverse Effect; (C)&nbsp;possess all material Authorizations necessary for its operations as
currently conducted and such Authorizations are valid and in full force and effect and neither the Company nor the Subsidiaries is in
material violation of any term of any such Authorizations; (D)&nbsp;have not received written notice of any claim, action, suit, proceeding,
hearing, enforcement, investigation, arbitration or other action from the FDA, the EMA, or any other federal, state, local or foreign
governmental or regulatory authority or third party alleging that any Company product, operation or activity is in material violation
of any Applicable Laws or Authorizations; (E)&nbsp;have not received written notice that the FDA, EMA, or any other federal, state, local
or foreign governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any
material Authorizations; and (F)&nbsp;have filed, obtained, maintained or submitted all reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations except where the failure
to file such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments would not result
in a Material Adverse Effect, and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements
or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">bb.&#9;&#8239;&#8239;&#8239;&#8239;&nbsp;<U>Clinical
Studies</U>. The preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending
are, to the Company&#8217;s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance
with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials
of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results
of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete
in all material respects; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other
domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical
trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of
which are referred to in the Registration Statement and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cc.&#9;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Environmental
Laws</U>. The Company and the Subsidiaries (i)&nbsp;are in compliance with any and all applicable federal, state, local and foreign laws,
rules, regulations, decisions and orders relating to the protection of human health and safety, the environment or hazardous or toxic
substances or wastes, pollutants or contaminants (collectively, &#8220;<U>Environmental Laws</U>&#8221;); (ii)&nbsp;have received and
are in compliance with all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their
respective businesses as described in the Registration Statement and the Prospectus; and (iii)&nbsp;have not received notice of any actual
or potential liability for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants
or contaminants, except, in the case of any of clauses (i), (ii)&nbsp;or (iii)&nbsp;above, for any such failure to comply or failure
to receive required permits, licenses, other approvals or liability as would not, individually or in the aggregate, have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dd.&#9;&#8239;&#8239;&#8239;&#8239;&nbsp;<U>Internal
Controls; Disclosure Controls</U>. The Company maintains a system of internal accounting controls sufficient to provide reasonable assurance
that (i)&nbsp;transactions are executed in accordance with management&#8217;s general or specific authorizations; (ii)&nbsp;transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability;
(iii)&nbsp;access to assets is permitted only in accordance with management&#8217;s general or specific authorization; and (iv)&nbsp;the
recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with
respect to any differences. The Company is not aware of any material weaknesses in its internal control over financial reporting (other
than as set forth in the Registration Statement or the Prospectus). Since the date of the latest audited financial statements of the
Company included in the Prospectus, there has been no change in the Company&#8217;s internal control over financial reporting that has
materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting (other
than as set forth in the Registration Statement or the Prospectus). The Company has established disclosure controls and procedures (as
defined in Exchange Act Rules&nbsp;13a-15 and 15d-15) that comply in all material respects with the requirements of the Exchange Act.
The Company&#8217;s certifying officers have evaluated the effectiveness of the Company&#8217;s controls and procedures as of a date
within 90 days prior to the filing date of the Form&nbsp;10-K for the fiscal year most recently ended (such date, the &#8220;<U>Evaluation
Date</U>&#8221;). The Company presented in its Form&nbsp;10-K for the fiscal year most recently ended the conclusions of the certifying
officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the most recent Evaluation
Date, and the &#8220;disclosure controls and procedures&#8221; are effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ee.&#9;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Sarbanes-Oxley
Act</U>. There is and has been no failure on the part of the Company or, to the knowledge of the Company, any of the Company&#8217;s
directors or officers, in their capacities as such, to comply in all material respects with any applicable provisions of the Sarbanes-Oxley
Act and the rules&nbsp;and regulations promulgated thereunder. Each of the principal executive officer and the principal financial officer
of the Company (or each former principal executive officer of the Company and each former principal financial officer of the Company
as applicable) has made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act with respect to all reports, schedules,
forms, statements and other documents required to be filed by it or furnished by it to the Commission during the past 12 months. For
purposes of the preceding sentence, &#8220;principal executive officer&#8221; and &#8220;principal financial officer&#8221; shall have
the meanings given to such terms in the Exchange Act Rules&nbsp;13a-15 and 15d-15.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ff.&#9;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Finder&#8217;s
Fees</U>. Neither the Company nor any Subsidiary has incurred any liability for any finder&#8217;s fees, brokerage commissions or similar
payments in connection with the transactions herein contemplated, except as may otherwise exist with respect to the Agents pursuant to
this Agreement and as were payable in connection with the At Market Sales Issuance Agreement, dated December&nbsp;30, 2022, between the
Company and B. Riley Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">gg.&#9;&#8239;&#8239;&#8239;&#8239;
 &#8239;<U>Labor Disputes</U>. No labor disturbance by or dispute with employees of the Company or any Subsidiary exists or, to the
knowledge of the Company, is threatened which would result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hh.&#9;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Investment
Company Act</U>. Neither the Company nor any Subsidiary is or, after giving effect to the offering and sale of the Placement Shares,
will be required to register as an &#8220;investment company&#8221; or an entity &#8220;controlled&#8221; by an &#8220;investment company,&#8221;
as such terms are defined in the Investment Company Act of 1940, as amended (the &#8220;<U>Investment Company Act</U>&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Operations</U>.
The operations of the Company and the Subsidiaries are and have been conducted at all times in compliance with applicable financial record
keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes
of all jurisdictions to which the Company or the Subsidiaries are subject, the rules&nbsp;and regulations thereunder and any related
or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency having jurisdiction over the
Company (collectively, the &#8220;<U>Money Laundering Laws</U>&#8221;), except where the failure to be in such compliance would not result
in a Material Adverse Effect; and no action, suit or proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company,
threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jj.&#9;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Off-Balance
Sheet Arrangements</U>. There are no transactions, arrangements and other relationships between and/or among the Company, and/or, to
the knowledge of the Company, any of its affiliates and any unconsolidated entity, including, but not limited to, any structured finance,
special purpose or limited purpose entity (each, an &#8220;<U>Off Balance Sheet Transaction</U>&#8221;) that would affect materially
the Company&#8217;s liquidity or the availability of or requirements for its capital resources, including those Off Balance Sheet Transactions
described in the Commission&#8217;s Statement about Management&#8217;s Discussion and Analysis of Financial Conditions and Results of
Operations (Release Nos. 33-8056; 34-45321; FR-61), required to be described in the Registration Statement or the Prospectus which have
not been described as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">kk.&#9;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Underwriter
Agreements</U>. Other than with respect to this Agreement, upon the effectiveness of this Agreement, the Company is not a party to any
agreement with an agent or underwriter for any other &#8220;at the market&#8221; or continuous equity transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ll.&#9;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>ERISA</U>.
To the knowledge of the Company, (i)&nbsp;each material employee benefit plan, within the meaning of Section&nbsp;3(3)&nbsp;of the Employee
Retirement Income Security Act of 1974, as amended (&#8220;<U>ERISA</U>&#8221;) that is maintained, administered or contributed to by
the Company or any of its affiliates for employees or former employees of the Company and the Subsidiaries has been maintained in material
compliance with its terms and the requirements of any applicable statutes, orders, rules&nbsp;and regulations, including but not limited
to ERISA and the Internal Revenue Code of 1986, as amended (the &#8220;<U>Code</U>&#8221;); (ii)&nbsp;no prohibited transaction, within
the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred which would result in a material liability to
the Company with respect to any such plan excluding transactions effected pursuant to a statutory or administrative exemption; and (iii)&nbsp;for
each such plan that is subject to the funding rules&nbsp;of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no &#8220;accumulated
funding deficiency&#8221; as defined in Section&nbsp;412 of the Code has been incurred, whether or not waived, and the fair market value
of the assets of each such plan (excluding for these purposes accrued but unpaid contributions) equals or exceeds the present value of
all benefits accrued under such plan determined using reasonable actuarial assumptions, other than, in the case of (i), (ii)&nbsp;and
(iii)&nbsp;above, as would not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mm.&#9;&#8239;&#8239;&#8239;&#8239;<U>Forward-Looking
Statements</U>. No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the
Exchange Act) (a&nbsp;&#8220;<U>Forward-Looking Statement</U>&#8221;) contained in the Registration Statement and the Prospectus has
been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">nn.&#9;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Margin
Rules</U>. Neither the issuance, sale and delivery of the Placement Shares nor the application of the proceeds thereof by the Company
as described in the Registration Statement and the Prospectus will, to the Company&#8217;s knowledge, violate Regulation T, U or X of
the Board of Governors of the Federal Reserve System.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">oo.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Insurance</U>.
The Company and the Subsidiaries carry, or are covered by, insurance in such amounts and covering such risks as the Company and the Subsidiaries
reasonably believe are adequate for the conduct of their business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pp.&#9;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Improper Practices</U>. (i)&nbsp;Neither the Company nor, to the Company&#8217;s knowledge, the Subsidiaries, nor to the Company&#8217;s
knowledge, any of their respective executive officers has, in the past five years, made any unlawful contributions to any candidate for
any political office (or failed fully to disclose any contribution in violation of law) or made any contribution or other payment to
any official of, or candidate for, any federal, state, municipal, or foreign office or other person charged with similar public or quasi-public
duty in violation of any law or of the character required to be disclosed in the Prospectus; (ii)&nbsp;no relationship, direct or indirect,
exists between or among the Company or, to the Company&#8217;s knowledge, the Subsidiaries or any affiliate of any of them, on the one
hand, and the directors, officers and stockholders of the Company or, to the Company&#8217;s knowledge, the Subsidiaries, on the other
hand, that is required by the Securities Act to be described in the Registration Statement and the Prospectus that is not so described;
(iii)&nbsp;no relationship, direct or indirect, exists between or among the Company or the Subsidiaries or any affiliate of them, on
the one hand, and the directors, officers, stockholders or directors of the Company or, to the Company&#8217;s knowledge, the Subsidiaries,
on the other hand, that is required by the rules&nbsp;of FINRA to be described in the Registration Statement and the Prospectus that
is not so described; (iv)&nbsp;there are no material outstanding loans or advances or material guarantees of indebtedness by the Company
or, to the Company&#8217;s knowledge, the Subsidiaries to or for the benefit of any of their respective officers or directors or any
of the members of the families of any of them; and (v)&nbsp;the Company has not offered, or caused any placement agent to offer, Common
Stock to any person with the intent to influence unlawfully (A)&nbsp;a customer or supplier of the Company or the Subsidiaries to alter
the customer&#8217;s or supplier&#8217;s level or type of business with the Company or the Subsidiaries or (B)&nbsp;a trade journalist
or publication to write or publish favorable information about the Company or the Subsidiaries or any of their respective products or
services, and, (vi)&nbsp;neither the Company nor the Subsidiaries nor, to the Company&#8217;s knowledge, any employee or agent of the
Company or the Subsidiaries has made any payment of funds of the Company or the Subsidiaries or received or retained any funds in violation
of any law, rule&nbsp;or regulation (including, without limitation, the Foreign Corrupt Practices Act of 1977), which payment, receipt
or retention of funds is of a character required to be disclosed in the Registration Statement or the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">qq.&#9;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Status
Under the Securities Act</U>. The Company was not and is not an ineligible issuer as defined in Rule&nbsp;405 under the Securities Act
at the times specified in Rules&nbsp;164 and 433 under the Securities Act in connection with the offering of the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">rr.&#9;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Misstatement or Omission in an Issuer Free Writing Prospectus</U>. Each Issuer Free Writing Prospectus, as of its issue date and as of
each Applicable Time (as defined in <U>Section&nbsp;25</U> below), did not, does not and will not, through the completion of the Placement
or Placements for which such Issuer Free Writing Prospectus is issued, include any information that conflicted, conflicts or will conflict
with the information contained in the Registration Statement or the Prospectus, including any incorporated document deemed to be a part
thereof that has not been superseded or modified. The foregoing sentence does not apply to statements in or omissions from any Issuer
Free Writing Prospectus based upon and in conformity with written information furnished to the Company by the Agents specifically for
use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ss.&#9;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Conflicts</U>. Neither the execution of this Agreement, nor the issuance, offering or sale of the Placement Shares, nor the consummation
of any of the transactions contemplated herein, nor the compliance by the Company with the terms and provisions hereof will conflict
with, or will result in a breach of, any of the terms and provisions of, or has constituted or will constitute a default under, or has
resulted in or will result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company
pursuant to the terms of any contract or other agreement to which the Company may be bound or to which any of the property or assets
of the Company is subject, except (i)&nbsp;such conflicts, breaches or defaults as may have been waived and (ii)&nbsp;such conflicts,
breaches and defaults that would not have a Material Adverse Effect; nor will such action result (x)&nbsp;in any violation of the provisions
of the organizational or governing documents of the Company, or (y)&nbsp;in any material violation of the provisions of any statute or
any order, rule&nbsp;or regulation applicable to the Company or of any court or of any federal, state or other regulatory authority or
other government body having jurisdiction over the Company, except where such violation would not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tt.&#9;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>OFAC</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Neither
the Company nor any Subsidiary (collectively, the &#8220;<U>Entity</U>&#8221;) nor any director or officer of the Entity nor, to the
Company&#8217;s knowledge, any employee, agent, affiliate or representative of the Entity, is a government, individual, or entity (in
this paragraph (tt), &#8220;<U>Person</U>&#8221;) that is, or is owned or controlled by a Person that is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
subject of any sanctions administered or enforced by the U.S. Department of Treasury&#8217;s Office of Foreign Assets Control (&#8220;<U>OFAC</U>&#8221;),
the United Nations Security Council (&#8220;<U>UNSC</U>&#8221;), the European Union (&#8220;<U>EU</U>&#8221;), His Majesty&#8217;s Treasury
(&#8220;<U>HMT</U>&#8221;), or other relevant sanctions authority (collectively, &#8220;<U>Sanctions</U>&#8221;), nor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;located,
organized or resident in a country or territory that is the subject of Sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Entity will not, directly or indirectly, knowingly use the proceeds of the offering, or lend, contribute or otherwise make available
such proceeds to any subsidiary, joint venture partner or other Person:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding
or facilitation, is the subject of Sanctions; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether
as underwriter, advisor, investor or otherwise).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;The
Entity represents and covenants that, except as detailed in the Registration Statement and the Prospectus, for the past 5 years, it has
not knowingly engaged in and is not now knowingly engaged in any dealing or transactions with any Person, or in any country or territory,
that at the time of the dealing or transaction is or was the subject of Sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">uu.&#9;&#8239;&#8239;&#8239;&#8239;&nbsp;<U>Stock
Transfer Taxes</U>. On each Settlement Date, all material stock transfer or other taxes (other than income taxes) which are required
to be paid in connection with the sale and transfer of the Placement Shares to be sold hereunder will be, or will have been, fully paid
or provided for by the Company and all laws imposing such taxes will be or will have been fully complied with by the Company in all material
respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vv.&#9;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>IT
Systems</U>. (i)(x)&nbsp;To the knowledge of Company, since December&nbsp;31, 2022, there has been no security breach or other compromise
of any Company&#8217;s information technology and computer systems, networks, hardware, software, data (including the data of their respective
customers, employees, suppliers, vendors and any third party data maintained by or on behalf of them), equipment or technology (collectively,
 &#8220;<U>IT Systems and Data</U>&#8221;) and (y)&nbsp;the Company has not been notified of, and has no knowledge of any event or condition
that would reasonably be expected to result in, any security breach or other compromise to their IT Systems and Data; (ii)&nbsp;the Company
is presently in material compliance with all applicable laws or statutes and all judgments, orders, rules&nbsp;and regulations of any
court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and
security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or
modification, except as would not, in the case of this clause (ii), individually or in the aggregate, have a Material Adverse Effect;
and (iii)&nbsp;the Company has implemented backup and disaster recovery technology consistent with industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ww.&#9;&#8239;&#8239;&#8239;&#8239;<U>Compliance
with Data Privacy Laws</U>. The Company and its subsidiaries are in material compliance with all applicable state and federal data privacy
and security laws and regulations, including, without limitation, HIPAA, CCPA, and the European Union General Data Protection Regulation
(&#8220;<U>GDPR</U>&#8221;) (EU 2016/679) (collectively, the &#8220;<U>Privacy Laws</U>&#8221;). Neither the Company nor any Subsidiary:
(i)&nbsp;has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any Privacy
Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;is currently
conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law;
or (iii)&nbsp;is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
certificate signed by an officer of the Company and delivered to the Agents or to counsel for the Agents pursuant to or in connection
with this Agreement shall be deemed to be a representation and warranty by the Company, as applicable, to the Agents as to the matters
set forth therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Covenants
of the Company</U>. The Company covenants and agrees with the Agents that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Registration
Statement Amendments</U>. After the date of this Agreement and during any period in which a prospectus relating to any Placement Shares
is required to be delivered by the Agents under the Securities Act (including in circumstances where such requirement may be satisfied
pursuant to Rule&nbsp;172 under the Securities Act) (the &#8220;<U>Prospectus Delivery Period</U>&#8221;) (i)&nbsp;the Company will notify
the Agents promptly of the time when any subsequent amendment to the Registration Statement, other than documents incorporated by reference
or amendments not related to any Placement, has been filed with the Commission and/or has become effective or any subsequent supplement
to the Prospectus has been filed and of any request by the Commission for any amendment or supplement to the Registration Statement or
Prospectus related to the Placement or for additional information related to the Placement, (ii)&nbsp;the Company will prepare and file
with the Commission, promptly upon the Agents&#8217; request, any amendments or supplements to the Registration Statement or Prospectus
that, upon the advice of the Company&#8217;s legal counsel, may be necessary or advisable in connection with the distribution of the
Placement Shares by the Agents (<I>provided, however</I>, that the failure of the Agents to make such request shall not relieve the Company
of any obligation or liability hereunder, or affect the Agents&#8217; right to rely on the representations and warranties made by the
Company in this Agreement and provided, further, that the only remedy the Agents shall have with respect to the failure to make such
filing shall be to cease making sales under this Agreement until such amendment or supplement is filed); (iii)&nbsp;the Company will
not file any amendment or supplement to the Registration Statement or Prospectus relating to the Placement Shares or a security convertible
into the Placement Shares (other than an Incorporated Document) unless a copy thereof has been submitted to the Agents within a reasonable
period of time before the filing and the Agents have not reasonably objected thereto (<I>provided, however</I>, that (A)&nbsp;the failure
of the Agents to make such objection shall not relieve the Company of any obligation or liability hereunder, or affect the Agents&#8217;
right to rely on the representations and warranties made by the Company in this Agreement and (B)&nbsp;the Company has no obligation
to provide the Agents any advance copy of such filing or to provide the Agents an opportunity to object to such filing if the filing
does not name the Agents or does not relate to the transaction herein provided; and provided, further, that the only remedy the Agents
shall have with respect to the failure by the Company to obtain such consent shall be to cease making sales under this Agreement) and
the Company will furnish to the Agents at the time of filing thereof a copy of any document that upon filing is deemed to be incorporated
by reference into the Registration Statement or Prospectus, except for those documents available via EDGAR; and (iv)&nbsp;the Company
will cause each amendment or supplement to the Prospectus to be filed with the Commission as required pursuant to the applicable paragraph
of Rule&nbsp;424(b)&nbsp;of the Securities Act or, in the case of any document to be incorporated therein by reference, to be filed with
the Commission as required pursuant to the Exchange Act, within the time period prescribed (the determination to file or not file any
amendment or supplement with the Commission under this <U>Section&nbsp;7(a)</U>, based on the Company&#8217;s reasonable opinion or reasonable
objections, shall be made exclusively by the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notice
of Commission Stop Orders</U>. The Company will advise the Agents, promptly after it receives notice or obtains knowledge thereof, of
the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement, of
the suspension of the qualification of the Placement Shares for offering or sale in any jurisdiction, or of the initiation or threatening
of any proceeding for any such purpose; and it will use its commercially reasonable efforts to prevent the issuance of any stop order
or to obtain its withdrawal if such a stop order should be issued. The Company will advise the Agents promptly after it receives any
request by the Commission for any amendments to the Registration Statement or any amendment or supplements to the Prospectus or any Issuer
Free Writing Prospectus or for additional information related to the offering of the Placement Shares or for additional information related
to the Registration Statement, the Prospectus or any Issuer Free Writing Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Delivery
of Prospectus; Subsequent Changes</U>. During the Prospectus Delivery Period, the Company will comply with all requirements imposed upon
it by the Securities Act, as from time to time in force, and to file on or before their respective due dates all reports and any definitive
proxy or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d)&nbsp;or
any other provision of or under the Exchange Act. If the Company has omitted any information from the Registration Statement pursuant
to Rule&nbsp;430A under the Securities Act, it will use its commercially reasonable efforts to comply with the provisions of and make
all requisite filings with the Commission pursuant to said Rule&nbsp;430A and to notify the Agents promptly of all such filings. If during
the Prospectus Delivery Period any event occurs as a result of which the Prospectus as then amended or supplemented would include an
untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances
then existing, not misleading, or if during such Prospectus Delivery Period it is necessary to amend or supplement the Registration Statement
or Prospectus to comply with the Securities Act, the Company will promptly notify the Designated Agent to suspend the offering of Placement
Shares during such period and the Company will promptly amend or supplement the Registration Statement or Prospectus (at the expense
of the Company) so as to correct such statement or omission or effect such compliance; <I>provided, however</I>, that the Company may
delay the filing of any amendment or supplement, if in the judgment of the Company, it is in the best interest of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Listing
of Placement Shares</U>. During the Prospectus Delivery Period, the Company will use its commercially reasonable efforts to cause the
Placement Shares to be listed on the Exchange and to qualify the Placement Shares for sale under the securities laws of such jurisdictions
in the United States as the Agents reasonably designates and to continue such qualifications in effect so long as required for the distribution
of the Placement Shares; <I>provided, however</I>, that the Company shall not be required in connection therewith to qualify as a foreign
corporation or dealer in securities, file a general consent to service of process, or subject itself to taxation in any jurisdiction
if it is not otherwise so subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Delivery
of Registration Statement and Prospectus</U>. The Company will furnish to the Agents and their counsel (at the reasonable expense of
the Company) copies of the Registration Statement, the Prospectus (including all documents incorporated by reference therein) and all
amendments and supplements to the Registration Statement or Prospectus that are filed with the Commission during the Prospectus Delivery
Period (including all documents filed with the Commission during such period that are deemed to be incorporated by reference therein),
in each case as soon as reasonably practicable and in such quantities as the Agents may from time to time reasonably request and, at
the Agents&#8217; request, will also furnish copies of the Prospectus to each exchange or market on which sales of the Placement Shares
may be made; <I>provided, however</I>, that the Company shall not be required to furnish any document (other than the Prospectus) to
the Agents to the extent such document is available on EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Earnings
Statement</U>. The Company will make generally available to its security holders as soon as practicable, but in any event not later than
15 months after the end of the Company&#8217;s current fiscal quarter, an earnings statement covering a 12-month period that satisfies
the provisions of Section&nbsp;11(a)&nbsp;and Rule&nbsp;158 of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Use
of Proceeds</U>. The Company will use the Net Proceeds as described in the Prospectus in the section titled &#8220;Use of Proceeds.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notice
of Other Sales</U>. Without the prior written consent of the Agents, the Company will not, directly or indirectly, offer to sell, sell,
contract to sell, grant any option to sell or otherwise dispose of any Common Stock (other than the Placement Shares offered pursuant
to this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or any rights to purchase or acquire, Common
Stock during the period beginning on the date on which any Placement Notice is delivered to an Agent hereunder and ending on the third
(3rd) Trading Day immediately following the final Settlement Date with respect to Placement Shares sold pursuant to such Placement Notice
(or, if the Placement Notice has been terminated or suspended prior to the sale of all Placement Shares covered by a Placement Notice,
the date of such suspension or termination); and will not directly or indirectly in any other &#8220;at the market&#8221; or continuous
equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Stock (other than
the Placement Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or
any rights to purchase or acquire, Common Stock prior to the termination of this Agreement; <I>provided, however</I>, that such restrictions
will not apply in connection with the Company&#8217;s issuance or sale of (i)&nbsp;Common Stock, options to purchase Common Stock, restricted
shares of Common Stock, restricted stock units or shares of Common Stock issuable upon the exercise of options or vesting of restricted
stock units pursuant to any stock option, equity incentive or benefits plan, stock ownership plan or dividend reinvestment plan (but
not Common Stock subject to a waiver to exceed plan limits in its dividend reinvestment plan) of the Company whether now in effect or
hereafter implemented; (ii)&nbsp;Common Stock issuable upon conversion of securities or the exercise of warrants, options or other rights
in effect or outstanding, and disclosed in filings by the Company available on EDGAR or otherwise in writing to the Agents, (iii)&nbsp;Common
Stock, or securities convertible into or exercisable for Common Stock, offered and sold in a privately negotiated transaction to vendors,
customers, strategic partners or potential strategic partners or other investors conducted in a manner so as not to be integrated with
the offering of Common Stock hereby and (iv)&nbsp;Common Stock in connection with any acquisition, strategic investment or other similar
transaction (including any joint venture, strategic alliance or partnership).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Change
of Circumstances</U>. The Company will, at any time during the pendency of a Placement Notice advise the Agents promptly after it shall
have received notice or obtained knowledge thereof, of any information or fact that would alter or affect in any material respect any
opinion, certificate, letter or other document required to be provided to the Agents pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Due
Diligence Cooperation</U>. During the term of this Agreement, the Company will cooperate with any reasonable due diligence review conducted
by the Agents or their representatives in connection with the transactions contemplated hereby, including, without limitation, providing
information and making available documents and senior corporate officers, during regular business hours and at the Company&#8217;s principal
offices, as the Agents may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Required
Filings Relating to Placement of Placement Shares</U>. The Company agrees that on such dates as the Securities Act shall require, the
Company will (i)&nbsp;file a prospectus supplement with the Commission under the applicable paragraph of Rule&nbsp;424(b)&nbsp;under
the Securities Act (each and every date a filing under Rule&nbsp;424(b)&nbsp;is made, a &#8220;<U>Filing Date</U>&#8221;), which prospectus
supplement will set forth, within the relevant period, the amount of Placement Shares sold through the Agents, the Net Proceeds to the
Company and the compensation payable by the Company to the Agents with respect to such Placement Shares, and (ii)&nbsp;deliver such number
of copies of each such prospectus supplement to each exchange or market on which such sales were effected as may be required by the rules&nbsp;or
regulations of such exchange or market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Representation
Dates; Certificate</U>. Each time during the term of this Agreement that the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;amends
or supplements (other than a prospectus supplement relating solely to an offering of securities other than the Placement Shares) the
Registration Statement or the Prospectus relating to the Placement Shares by means of a post-effective amendment, sticker, or supplement
but not by means of incorporation of documents by reference into the Registration Statement or the Prospectus relating to the Placement
Shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;files
an annual report on Form&nbsp;10-K under the Exchange Act (including any Form&nbsp;10-K/A containing amended audited financial information
or a material amendment to the previously filed Form&nbsp;10-K);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;files
its quarterly reports on Form&nbsp;10-Q under the Exchange Act; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;files
a current report on Form&nbsp;8-K containing amended financial information (other than information &#8220;furnished&#8221; pursuant to
Items 2.02 or 7.01 of Form&nbsp;8-K or to provide disclosure pursuant to Item 8.01 of Form&nbsp;8-K relating to the reclassification
of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No.&nbsp;144) under the
Exchange Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Each
date of filing of one or more of the documents referred to in clauses (i)&nbsp;through (iv)&nbsp;shall be a &#8220;<U>Representation
Date</U>.&#8221;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Company shall furnish the Agents (but in the case of clause (iv)&nbsp;above only if any Agent reasonably determines that the information
contained in such Form&nbsp;8-K is material) with a certificate, in the form attached hereto as <U>Exhibit&nbsp;7(1)</U>. The requirement
to provide a certificate under this <U>Section&nbsp;7(1)</U>&nbsp;shall be waived for any Representation Date occurring at a time at
which no Placement Notice is pending, which waiver shall continue until the earlier to occur of the date the Company delivers a Placement
Notice hereunder (which for such calendar quarter shall be considered a Representation Date) and the next occurring Representation Date
on which the Company files its annual report on Form&nbsp;10-K. Notwithstanding the foregoing, (i)&nbsp;upon the delivery of the first
Placement Notice hereunder and (ii)&nbsp;if the Company subsequently decides to sell Placement Shares following a Representation Date
when the Company relied on such waiver and did not provide the Agents with a certificate under this <U>Section&nbsp;7(1)</U>, then before
the Agents sell any Placement Shares, the Company shall provide the Agents with a certificate, in the form attached hereto as <U>Exhibit&nbsp;7(1)</U>,
dated the date of the Placement Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Legal
Opinion</U>. On or prior to the date of the first Placement Notice given hereunder the Company shall cause to be furnished to the Agents
a written opinion and a negative assurance letter of Troutman Pepper Locke LLP (&#8220;<U>Company Counsel</U>&#8221;), or other counsel
reasonably satisfactory to the Agents, each in form and substance reasonably satisfactory to the Agents. Thereafter, within five (5)&nbsp;Trading
Days of each Representation Date with respect to which the Company is obligated to deliver a certificate in the form attached hereto
as Exhibit&nbsp;7(l)&nbsp;for which no waiver is applicable, the Company shall cause to be furnished to the Agents a&nbsp;negative assurance
letter of Company Counsel in form and substance reasonably satisfactory to the Agents; provided that, in lieu of such negative assurance
for subsequent periodic filings under the Exchange Act, counsel may furnish the Agents with a letter (a&nbsp;&#8220;<U>Reliance Letter</U>&#8221;)
to the effect that the Agents may rely on the negative assurance letter previously delivered under this Section&nbsp;7(m)&nbsp;to the
same extent as if it were dated the date of such letter (except that statements in such prior letter shall be deemed to relate to the
Registration Statement and the Prospectus as amended or supplemented as of the date of the Reliance Letter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Comfort
Letter</U>. On or prior to the date of the first Placement Notice given hereunder and within five (5)&nbsp;Trading Days after each subsequent
Representation Date, other than pursuant to Section&nbsp;7(l)(iii)&nbsp;and other than in connection with the filing and effectiveness
of a replacement Registration Statement on Form&nbsp;S-3 during the six-month period following the date hereof, the Company shall cause
its independent accountants to furnish the Agents letters (the &#8220;<U>Comfort Letters</U>&#8221;), dated the date the Comfort Letter
is delivered, which shall meet the requirements set forth in this <U>Section&nbsp;7(n)</U>. The Comfort Letter from the Company&#8217;s
independent accountants shall be in a form and substance reasonably satisfactory to the Agents, (i)&nbsp;confirming that they are an
independent public accounting firm within the meaning of the Securities Act and the Public Company Accounting Oversight Board (the &#8220;<U>PCAOB</U>&#8221;),
(ii)&nbsp;stating, as of such date, the conclusions and findings of such firm with respect to the financial information and other matters
ordinarily covered by accountants&#8217; &#8220;comfort letters&#8221; to underwriters in connection with registered public offerings
(the first such letter, the &#8220;<U>Initial Comfort Letter</U>&#8221;) and (iii)&nbsp;updating the Initial Comfort Letter with any
information that would have been included in the Initial Comfort Letter had it been given on such date and modified as necessary to relate
to the Registration Statement and the Prospectus, as amended and supplemented to the date of such letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Market
Activities</U>. The Company will not, directly or indirectly, (i)&nbsp;take any action designed to cause or result in, or that constitutes
or would constitute, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of
Common Stock or (ii)&nbsp;sell, bid for, or purchase Common Stock in violation of Regulation M, or pay anyone any compensation for soliciting
purchases of the Placement Shares other than the Agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Investment
Company Act</U>. The Company will conduct its affairs in such a manner so as to reasonably ensure that neither it nor the Subsidiaries
will be or become, at any time prior to the termination of this Agreement, an &#8220;investment company,&#8221; as such term is defined
in the Investment Company Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Offer to Sell</U>. Other than an Issuer Free Writing Prospectus approved in advance by the Company and the Agents in their capacity as
agents hereunder pursuant to <U>Section&nbsp;23</U>, neither of the Agents nor the Company (including its agents and representatives,
other than the Agents in their capacity as such) will make, use, prepare, authorize, approve or refer to any written communication (as
defined in Rule&nbsp;405), required to be filed with the Commission, that constitutes an offer to sell or solicitation of an offer to
buy Placement Shares hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Sarbanes-Oxley
Act</U>. The Company will maintain and keep accurate books and records reflecting its assets and maintain internal accounting controls
in a manner designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with GAAP and including those policies and procedures that (i)&nbsp;pertain to the maintenance
of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company, (ii)&nbsp;provide
reasonable assurance that transactions are recorded as necessary to permit the preparation of the Company&#8217;s consolidated financial
statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with management&#8217;s
and the Company&#8217;s directors&#8217; authorization, and (iii)&nbsp;provide reasonable assurance regarding prevention or timely detection
of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on its financial statements.
The Company will maintain disclosure controls and procedures that comply with the requirements of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Representations
and Covenants of the Agents</U>. Each of the Agents represents and warrants that it is duly registered as a broker-dealer under FINRA,
the Exchange Act and the applicable statutes and regulations of each state in which the Placement Shares will be offered and sold, except
such states in which such Agent is exempt from registration or such registration is not otherwise required. Each of the Agents shall
continue, for the term of this Agreement, to be duly registered as a broker-dealer under FINRA, the Exchange Act and the applicable statutes
and regulations of each state in which the Placement Shares will be offered and sold, except such states in which it is exempt from registration
or such registration is not otherwise required, during the term of this Agreement. Each of the Agents shall comply with all applicable
law and regulations in connection with the transactions contemplated by this Agreement, including the issuance and sale through such
Agent of the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Payment
of Expenses</U>. The Company will pay all expenses incident to the performance of its obligations under this Agreement, including (i)&nbsp;the
preparation, filing, including any fees required by the Commission, and printing of the Registration Statement (including financial statements
and exhibits) as originally filed and of each amendment and supplement thereto and each Free Writing Prospectus, in such number as the
Agents shall deem reasonably necessary, (ii)&nbsp;the printing and delivery to the Agents of this Agreement and such other documents
as may be required in connection with the offering, purchase, sale, issuance or delivery of the Placement Shares, (iii)&nbsp;the preparation,
issuance and delivery of the certificates, if any, for the Placement Shares to the Agents, including any stock or other transfer taxes
and any capital duties, stamp duties or other duties or taxes payable upon the sale, issuance or delivery of the Placement Shares to
the Agents, (iv)&nbsp;the fees and disbursements of the counsel, accountants and other advisors to the Company, (v)&nbsp;the reasonable
and documented out-of-pocket fees and disbursements of counsel to the Agents (x)&nbsp;not to exceed $75,000 in connection with the filing
of this Agreement and (y)&nbsp;not to exceed $7,500 per quarter thereafter in connection with updates at the time of Representation Dates;
(vi)&nbsp;the fees and expenses of the transfer agent and registrar for the Common Stock, (vii)&nbsp;the filing fees incident to any
review by FINRA of the terms of the sale of the Placement Shares, and (viii)&nbsp;the fees and expenses incurred in connection with the
listing of the Placement Shares on the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Conditions
to the Agents&#8217; Obligations</U>. The obligations of the Agents hereunder with respect to a Placement will be subject to the continuing
accuracy and completeness of the representations and warranties made by the Company herein (other than those representations and warranties
made as of a specified date or time), to the due performance in all material respects by the Company of its obligations hereunder, to
the completion by the Agents of a due diligence review satisfactory to it in its reasonable judgment, and to the continuing reasonable
satisfaction (or waiver by the Agents in their sole discretion) of the following additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Registration
Statement Effective</U>. The Registration Statement shall remain effective and shall be available for the sale of all Placement Shares
contemplated to be issued by any Placement Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Material Notices</U>. None of the following events shall have occurred and be continuing: (i)&nbsp;receipt by the Company of any request
for additional information from the Commission or any other federal or state governmental authority during the period of effectiveness
of the Registration Statement, the response to which would require any post&#45;effective amendments or supplements to the Registration
Statement or the Prospectus; (ii)&nbsp;the issuance by the Commission or any other federal or state governmental authority of any stop
order suspending the effectiveness of the Registration Statement or receipt by the Company of notification of the initiation of any proceedings
for that purpose; (iii)&nbsp;receipt by the Company of any notification with respect to the suspension of the qualification or exemption
from qualification of any of the Placement Shares for sale in any jurisdiction or receipt by the Company of notification of the initiation
of, or a threat to initiate, any proceeding for such purpose; or (iv)&nbsp;the occurrence of any event that makes any material statement
made in the Registration Statement or the Prospectus or any material Incorporated Document untrue in any material respect or that requires
the making of any changes in the Registration Statement, the Prospectus or any material Incorporated Document so that, in the case of
the Registration Statement, it will not contain any materially untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements therein not misleading and, that in the case of the Prospectus or any
material Incorporated Document, it will not contain any materially untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were
made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.&#8239;&#8239;&#8239;&#8239;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Misstatement or Material Omission</U>. The Agents shall not have advised the Company that the Registration Statement or Prospectus, or
any amendment or supplement thereto, contains an untrue statement of fact that in the Agents&#8217; reasonable opinion is material, or
omits to state a fact that in the Agents&#8217; reasonable opinion is material and is required to be stated therein or is necessary to
make the statements therein not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Material
Changes</U>. Except as contemplated in the Prospectus, or disclosed in the Company&#8217;s reports filed with the Commission, there shall
not have been any Material Adverse Effect, or any development that would cause a Material Adverse Effect, or a downgrading in or withdrawal
of the rating assigned to any of the Company&#8217;s securities (other than asset backed securities) by any &#8220;nationally recognized
statistical rating organization,&#8221; as such term is defined by the Commission for purposes of Rule&nbsp;436(g)(2)&nbsp;under the
Securities Act (a &#8220;<U>Rating Organization</U>&#8221;), or a public announcement by any Rating Organization that it has under surveillance
or review its rating of any of the Company&#8217;s securities (other than asset backed securities), the effect of which, in the case
of any such action by a Rating Organization described above, in the reasonable judgment of the Agents (without relieving the Company
of any obligation or liability it may otherwise have), is so material as to make it impracticable or inadvisable to proceed with the
offering of the Placement Shares on the terms and in the manner contemplated in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Company
Counsel Legal Opinion</U>. The Agents shall have received the opinion and negative assurance letter of Company Counsel required to be
delivered pursuant to <U>Section&nbsp;7(m)</U>&nbsp;on or before the date on which such delivery of such opinion and negative assurance
letter are required pursuant to <U>Section&nbsp;7(m)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Agents
Counsel Legal Opinion</U>. Agents shall have received from Duane Morris LLP, counsel for the Agents, such opinion or opinions, on or
before the date on which the delivery of the Company Counsel legal opinion is required pursuant to <U>Section&nbsp;7(m)</U>, with respect
to such matters as the Agents may reasonably require, and the Company shall have furnished to such counsel such documents as they request
for enabling them to pass upon such matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Comfort
Letter</U>. The Agents shall have received the Comfort Letter required to be delivered pursuant <U>Section&nbsp;7(n)</U>&nbsp;on or before
the date on which such delivery of such letter is required pursuant to <U>Section&nbsp;7(n)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Representation
Certificate</U>. The Agents shall have received the certificate required to be delivered pursuant to <U>Section&nbsp;7(1)</U>&nbsp;on
or before the date on which delivery of such certificate is required pursuant to <U>Section&nbsp;7(1)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Secretary&#8217;s
Certificate</U>. On or prior to the first Representation Date, the Agents shall have received a certificate, signed on behalf of the
Company by its corporate Secretary, in form and substance satisfactory to the Agents and their counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Suspension</U>. Trading in the Common Stock shall not have been suspended on the Exchange and the Common Stock shall not have been delisted
from the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Other
Materials</U>. On each date on which the Company is required to deliver a certificate pursuant to <U>Section&nbsp;7(1)</U>, the Company
shall have furnished to the Agents such appropriate further information, certificates and documents as the Agents may reasonably request
and which are usually and customarily furnished by an issuer of securities in connection with a securities offering of the type contemplated
hereby. All such opinions, certificates, letters and other documents will be in compliance with the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Securities
Act Filings Made</U>. All filings with the Commission required by Rule&nbsp;424 under the Securities Act to have been filed prior to
the issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for such filing by Rule&nbsp;424.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Approval
for Listing</U>. The Placement Shares shall either have been approved for listing on the Exchange, subject only to notice of issuance,
or the Company shall have filed an application for listing of the Placement Shares on the Exchange at, or prior to, the issuance of any
Placement Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Termination Event</U>. There shall not have occurred any event that would permit the Agents to terminate this Agreement pursuant to <U>Section&nbsp;13(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Indemnification
and Contribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Company
Indemnification</U>. The Company agrees to indemnify and hold harmless the Agents, their partners, members, directors, officers, employees
and agents and each person, if any, who controls the Agents within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20
of the Exchange Act as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, arising out of or based upon any untrue
statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), or the omission
or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading,
or arising out of any untrue statement or alleged untrue statement of a material fact included in any related Issuer Free Writing Prospectus
or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, to the extent of the aggregate amount
paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened,
or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided
that (subject to <U>Section&nbsp;11(d)</U>&nbsp;below) any such settlement is effected with the written consent of the Company, which
consent shall not unreasonably be delayed or withheld; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;against
any and all expense whatsoever, as incurred (including the reasonable and documented out-of-pocket fees and disbursements of counsel),
reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental
agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged
untrue statement or omission, to the extent that any such expense is not paid under (i)&nbsp;or (ii)&nbsp;above,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>provided,
however</I>, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out
of any untrue statement or omission or alleged untrue statement or omission made solely in reliance upon and in conformity with written
information furnished to the Company by any Agent expressly for use in the Registration Statement (or any amendment thereto), or in any
related Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Indemnification
by the Agents</U>. Each Agent, severally and not jointly, agrees to indemnify and hold harmless the Company and its directors and officers,
and each person, if any, who (i)&nbsp;controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20
of the Exchange Act or (ii)&nbsp;is controlled by or is under common control with the Company against any and all loss, liability, claim,
damage and expense described in the indemnity contained in <U>Section&nbsp;11(a)</U>, as incurred, but only with respect to untrue statements
or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendments thereto) or in any related
Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with information
relating to such Agent and furnished to the Company in writing by such Agent expressly for use therein. The Company hereby acknowledges
that the only information that the Agents have furnished to the Company expressly for use in the Registration Statement, the Prospectus,
any Prospectus Supplement or any Issuer Free Writing Prospectus (or any amendment or supplement thereto) are the statements set forth
in the third sentence of the eighth paragraph and the first sentence of the tenth paragraph under the caption &#8220;Plan of Distribution&#8221;
in the Prospectus (the &#8220;<U>Agents Information</U>&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Procedure</U>.
Any party that proposes to assert the right to be indemnified under this <U>Section&nbsp;11</U> will, promptly after receipt of notice
of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party or parties under
this <U>Section&nbsp;11</U>, notify each such indemnifying party of the commencement of such action, enclosing a copy of all papers served,
but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i)&nbsp;any liability that it might
have to any indemnified party otherwise than under this <U>Section&nbsp;11</U> and (ii)&nbsp;any liability that it may have to any indemnified
party under the foregoing provisions of this <U>Section&nbsp;11</U> unless, and only to the extent that, such omission results in the
forfeiture of substantive rights or defenses by the indemnifying party. If any such action is brought against any indemnified party and
it notifies the indemnifying party of its commencement, the indemnifying party will be entitled to participate in and, to the extent
that it elects by delivering written notice to the indemnified party promptly after receiving notice of the commencement of the action
from the indemnified party, jointly with any other indemnifying party similarly notified, to assume the defense of the action, with counsel
reasonably satisfactory to the indemnified party, and after notice from the indemnifying party to the indemnified party of its election
to assume the defense, the indemnifying party will not be liable to the indemnified party for any legal or other expenses except as provided
below and except for the reasonable costs of investigation subsequently incurred by the indemnified party in connection with the defense.
The indemnified party will have the right to employ its own counsel in any such action, but the fees, expenses and other charges of such
counsel will be at the expense of such indemnified party unless (1)&nbsp;the employment of counsel by the indemnified party has been
authorized in writing by the indemnifying party, (2)&nbsp;the indemnified party has reasonably concluded (based on advice of counsel)
that there may be legal defenses available to it or other indemnified parties that are different from or in addition to those available
to the indemnifying party, (3)&nbsp;a conflict or potential conflict of interest exists (based on advice of counsel to the indemnified
party) between the indemnified party and the indemnifying party (in which case the indemnifying party will not have the right to direct
the defense of such action on behalf of the indemnified party) or (4)&nbsp;the indemnifying party has not in fact employed counsel to
assume the defense of such action within a reasonable time after receiving notice of the commencement of the action, in each of which
cases the reasonable and documented out-of-pocket fees, disbursements and other charges of counsel will be at the expense of the indemnifying
party or parties. It is understood that the indemnifying party or parties shall not, in connection with any proceeding or related proceedings
in the same jurisdiction, be liable for the reasonable and documented out-of-pocket fees, disbursements and other charges of more than
one separate firm admitted to practice in such jurisdiction at any one time for all such indemnified party or parties. All such reasonable
and documented out-of-pocket fees, disbursements and other charges will be reimbursed by the indemnifying party promptly after the indemnifying
party receives a written invoice relating to fees, disbursements and other charges in reasonable detail. An indemnifying party will not,
in any event, be liable for any settlement of any action or claim effected without its written consent. No indemnifying party shall,
without the prior written consent of each indemnified party, settle or compromise or consent to the entry of any judgment in any pending
or threatened claim, action or proceeding relating to the matters contemplated by this <U>Section&nbsp;11</U> (whether or not any indemnified
party is a party thereto), unless such settlement, compromise or consent (1)&nbsp;includes an unconditional release of each indemnified
party from all liability arising out of such litigation, investigation, proceeding or claim and (2)&nbsp;does not include a statement
as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Contribution</U>.
In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing paragraphs
of this <U>Section&nbsp;11</U> is applicable in accordance with its terms but for any reason is held to be unavailable from the Company
or an Agent, the Company and such Agent will contribute to the total losses, claims, liabilities, expenses and damages (including any
investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of, any action, suit
or proceeding or any claim asserted, but after deducting any contribution received by the Company from persons other than the Agents,
such as persons who control the Company within the meaning of the Securities Act or the Exchange Act, officers of the Company who signed
the Registration Statement and directors of the Company, who also may be liable for contribution) to which the Company and such Agent
may be subject in such proportion as shall be appropriate to reflect the relative benefits received by the Company on the one hand and
such Agent on the other hand. The relative benefits received by the Company on the one hand and an Agent on the other hand shall be deemed
to be in the same proportion as the total Net Proceeds from the sale of the Placement Shares (before deducting expenses) received by
the Company bear to the total compensation received by such Agent (before deducting expenses) from the sale of Placement Shares on behalf
of the Company. If, but only if, the allocation provided by the foregoing sentence is not permitted by applicable law, the allocation
of contribution shall be made in such proportion as is appropriate to reflect not only the relative benefits referred to in the foregoing
sentence but also the relative fault of the Company, on the one hand, and such Agent, on the other hand, with respect to the statements
or omission that resulted in such loss, claim, liability, expense or damage, or action in respect thereof, as well as any other relevant
equitable considerations with respect to such offering. Such relative fault shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to
information supplied by the Company or such Agent, the intent of the parties and their relative knowledge, access to information and
opportunity to correct or prevent such statement or omission. The Company and each Agent agree that it would not be just and equitable
if contributions pursuant to this <U>Section&nbsp;11(d)</U>&nbsp;were to be determined by pro rata allocation or by any other method
of allocation that does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified
party as a result of the loss, claim, liability, expense, or damage, or action in respect thereof, referred to above in this <U>Section&nbsp;11(d)</U>&nbsp;shall
be deemed to include, for the purpose of this <U>Section&nbsp;11(d)</U>, any legal or other expenses reasonably incurred by such indemnified
party in connection with investigating or defending any such action or claim to the extent consistent with <U>Section&nbsp;11(c)</U>&nbsp;hereof.
Notwithstanding the foregoing provisions of this <U>Section&nbsp;11(d)</U>, an Agent shall not be required to contribute any amount in
excess of the commissions received by it under this Agreement and no person found guilty of fraudulent misrepresentation (within the
meaning of Section&nbsp;11(f)&nbsp;of the Securities Act) will be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation. For purposes of this <U>Section&nbsp;11(d)</U>, any person who controls a party to this Agreement within
the meaning of the Securities Act or the Exchange Act, and any officers, directors, partners, employees or agents of an Agent, will have
the same rights to contribution as that party, and each officer who signed the Registration Statement and director of the Company will
have the same rights to contribution as the Company, subject in each case to the provisions hereof. Any party entitled to contribution,
promptly after receipt of notice of commencement of any action against such party in respect of which a claim for contribution may be
made under this <U>Section&nbsp;11(d)</U>, will notify any such party or parties from whom contribution may be sought, but the omission
to so notify will not relieve that party or parties from whom contribution may be sought from any other obligation it or they may have
under this <U>Section&nbsp;11(d)</U>&nbsp;except to the extent that the failure to so notify such other party materially prejudiced the
substantive rights or defenses of the party from whom contribution is sought. Except for a settlement entered into pursuant to the last
sentence of <U>Section&nbsp;11(c)</U>&nbsp;hereof, no party will be liable for contribution with respect to any action or claim settled
without its written consent if such consent is required pursuant to <U>Section&nbsp;11(c)</U>&nbsp;hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Representations
and Agreements to Survive Delivery</U>. The indemnity and contribution agreements contained in Section&nbsp;11 of this Agreement and
all representations and warranties of the Company herein or in certificates delivered pursuant hereto shall survive, as of their respective
dates, regardless of (i)&nbsp;any investigation made by or on behalf of the Agents, any controlling persons, or the Company (or any of
their respective officers, directors or controlling persons), (ii)&nbsp;delivery and acceptance of the Placement Shares and payment therefor
or (iii)&nbsp;any termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;An
Agent may terminate this Agreement with respect to itself, by notice to the Company, as hereinafter specified at any time (1)&nbsp;if
there has been, since the time of execution of this Agreement or since the date as of which information is given in the Prospectus, any
Material Adverse Effect, or any development that would have a Material Adverse Effect that, in the sole judgment of such Agent, is material
and adverse and makes it impractical or inadvisable to market the Placement Shares or to enforce contracts for the sale of the Placement
Shares, (2)&nbsp;if there has occurred any material adverse change in the financial markets in the United States or the international
financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or development involving
a prospective change in national or international political, financial or economic conditions, in each case the effect of which is such
as to make it, in the judgment of such Agent, impracticable or inadvisable to market the Placement Shares or to enforce contracts for
the sale of the Placement Shares, (3)&nbsp;if trading in the Common Stock has been suspended or limited by the Commission or the Exchange,
or if trading generally on the Exchange has been suspended or limited, or minimum prices for trading have been fixed on the Exchange,
(4)&nbsp;if any suspension of trading of any securities of the Company on any exchange or in the over-the-counter market shall have occurred
and be continuing, (5)&nbsp;if a major disruption of securities settlements or clearance services in the United States shall have occurred
and be continuing, or (6)&nbsp;if a banking moratorium has been declared by either U.S. Federal or New York authorities. Any such termination
shall be without liability of any party to any other party except that the provisions of <U>Section</U>&nbsp;9 (Payment of Expenses),
<U>Section&nbsp;11</U> (Indemnification and Contribution), <U>Section&nbsp;12</U> (Representations and Agreements to Survive Delivery),
<U>Section&nbsp;18</U> (Governing Law and Time; Waiver of Jury Trial) and <U>Section&nbsp;19</U> (Consent to Jurisdiction) hereof shall
remain in full force and effect notwithstanding such termination. If an Agent elects to terminate this Agreement as provided in this
<U>Section&nbsp;13(a)</U>, such Agent shall provide the required notice as specified in <U>Section&nbsp;14</U> (Notices).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;The
Company shall have the right, by giving five (5)&nbsp;days&#8217; notice as hereinafter specified to terminate this Agreement in its
entirety or with respect to any one or multiple of the Agents, in its sole discretion at any time after the date of this Agreement. Any
such termination shall be without liability of any party to any other party except that the provisions of <U>Section&nbsp;9</U> (Payment
of Expenses), <U>Section&nbsp;11</U> (Indemnification and Contribution), <U>Section&nbsp;12</U> (Representations and Agreements to Survive
Delivery), <U>Section&nbsp;18</U> (Governing Law and Time; Waiver of Jury Trial) and <U>Section&nbsp;19</U> (Consent to Jurisdiction)
hereof shall remain in full force and effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
Agent shall have the right, by giving five (5)&nbsp;days&#8217; notice as hereinafter specified to terminate this Agreement with respect
to itself in its sole discretion at any time after the date of this Agreement. Any such termination shall be without liability of any
party to any other party except that the provisions of <U>Section&nbsp;9</U> (Payment of Expenses), <U>Section&nbsp;11</U> (Indemnification
and Contribution), <U>Section&nbsp;12</U> (Representations and Agreements to Survive Delivery), <U>Section&nbsp;18</U> (Governing Law
and Time; Waiver of Jury Trial) and <U>Section&nbsp;19</U> (Consent to Jurisdiction) hereof shall remain in full force and effect notwithstanding
such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Unless
earlier terminated pursuant to this <U>Section&nbsp;13</U>, this Agreement shall automatically terminate upon the issuance and sale of
all of the Placement Shares through the Agents on the terms and subject to the conditions set forth herein except that the provisions
of <U>Section&nbsp;9</U> (Payment of Expenses), <U>Section&nbsp;11</U> (Indemnification and Contribution), <U>Section&nbsp;12</U> (Representations
and Agreements to Survive Delivery), <U>Section&nbsp;18</U> (Governing Law and Time; Waiver of Jury Trial) and <U>Section&nbsp;19</U>
(Consent to Jurisdiction) hereof shall remain in full force and effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Agreement shall remain in full force and effect unless terminated pursuant to <U>Sections 13(a)</U>, <U>(b</U>), <U>(c</U>), or <U>(d)</U>&nbsp;above
or otherwise by mutual agreement of the parties; <I>provided, however</I>, that any such termination by mutual agreement shall in all
cases be deemed to provide that <U>Section&nbsp;9</U> (Payment of Expenses), <U>Section&nbsp;11</U> (Indemnification and Contribution),
<U>Section&nbsp;12</U> (Representations and Agreements to Survive Delivery), <U>Section&nbsp;18</U> (Governing Law and Time; Waiver of
Jury Trial) and <U>Section&nbsp;19</U> (Consent to Jurisdiction) shall remain in full force and effect. Upon termination of this Agreement,
the Company shall not have any liability to an Agent for any discount, commission or other compensation with respect to any Placement
Shares not otherwise sold by an Agent under this Agreement. To the extent this Agreement is terminated by one Agent or by the Company
with respect to one Agent pursuant to <U>Sections 13(a)</U>,&nbsp;<U>(b)</U>&nbsp;or <U>(c)</U>&nbsp;above, this Agreement shall terminate
only with respect to such Agent and shall remain in full force and effect with respect to the Company and the other Agents, unless and
until terminated pursuant to <U>Sections 13(a)</U>, <U>(b)</U>, <U>(c)</U>, or <U>(d)</U>&nbsp;above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Any
termination of this Agreement shall be effective on the date specified in such notice of termination; <I>provided, however</I>, that
such termination shall not be effective until the close of business on the date of receipt of such notice by an Agent or the Company,
plus any required notice period as specified in this <U>Section&nbsp;13</U>, as the case may be. If such termination shall occur prior
to the Settlement Date for any sale of Placement Shares, such Placement Shares shall settle in accordance with the provisions of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notices</U>.
All notices or other communications required or permitted to be given by any party to any other party pursuant to the terms of this Agreement
shall be in writing, unless otherwise specified, and if sent to the Agents, shall be delivered to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
    Riley Securities,&nbsp;Inc.&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">299
    Park Avenue, 21st Floor&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10171&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:&#8239;&#8239;&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lake
    Street Capital Markets, LLC&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">121
    South 8th Street, Suite&nbsp;1000&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minneapolis,
    MN 55402&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:&#8239;&#8239;
    &#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duane
    Morris LLP&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22
    Vanderbilt&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">335
    Madison Avenue, 23rd Floor&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10017&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:&#8239;&#8239;
    &#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
if to the Company, shall be delivered to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Journey
    Medical Corporation&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9237
    E Via de Ventura Blvd., Suite&nbsp;105&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scottsdale,
    AZ 85258&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Troutman
    Pepper Locke LLP&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">301
    S College Street, Suite&nbsp;3400&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charlotte,
    NC 28202</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address
for such purpose. Each such notice or other communication shall be deemed given (i)&nbsp;when delivered personally or by email (if receipt
of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) on or
before 4:30 p.m., New York City time, on a Business Day or, if such day is not a Business Day, on the next succeeding Business Day, (ii)&nbsp;on
the next Business Day after timely delivery to a nationally-recognized overnight courier and (iii)&nbsp;on the Business Day actually
received if deposited in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid). For purposes of this
Agreement, &#8220;<U>Business Day</U>&#8221; shall mean any day on which the Exchange and commercial banks in the City of New York are
open for business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Successors
and Assigns</U>. This Agreement shall inure to the benefit of and be binding upon the Company and each Agent and their respective successors
and the affiliates, controlling persons, officers and directors referred to in <U>Section&nbsp;11</U> hereof. References to any of the
parties contained in this Agreement shall be deemed to include the successors and permitted assigns of such party. Nothing in this Agreement,
express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assigns
any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.
Neither the Company nor the Agents may assign its rights or obligations under this Agreement without the prior written consent of the
other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Adjustments
for Stock Splits</U>. The parties acknowledge and agree that all share&#45;related numbers contained in this Agreement shall be adjusted
to take into account any share consolidation, stock split, stock dividend, corporate domestication or similar event effected with respect
to the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Entire
Agreement; Amendment; Severability</U>. This Agreement (including all schedules and exhibits attached hereto and Placement Notices issued
pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings, both
written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement nor any term hereof may be
amended except pursuant to a written instrument executed by the Company and the Agents. In the event that any one or more of the provisions
contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court of
competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal
and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or unenforceable
term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder of the terms
and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>GOVERNING
LAW AND TIME; WAIVER OF JURY TRIAL</U>. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF
NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. THE COMPANY AND EACH
AGENT EACH HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL
PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>CONSENT
TO JURISDICTION</U>. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING
IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH ANY TRANSACTION CONTEMPLATED
HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY
SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT FORUM OR THAT THE VENUE
OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS
BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF (CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED)
TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND
SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS
IN ANY MANNER PERMITTED BY LAW.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Use
of Information</U>. The Agents may not use any information gained in connection with this Agreement and the transactions contemplated
by this Agreement, including due diligence, to advise any party with respect to transactions not expressly approved by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Counterparts</U>.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile transmission
or email of a .pdf attachment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Effect
of Headings</U>. The section, Schedule and Exhibit&nbsp;headings herein are for convenience only and shall not affect the construction
hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Permitted
Free Writing Prospectuses</U>. The Company represents, warrants and agrees that, unless it obtains the prior consent of each Agent, and
each Agent represents, warrants and agrees that, unless it obtains the prior consent of the Company, it has not made and will not make
any offer relating to the Placement Shares that would constitute an Issuer Free Writing Prospectus, or that would otherwise constitute
a &#8220;free writing prospectus,&#8221; as defined in Rule&nbsp;405, required to be filed with the Commission. Any such free writing
prospectus consented to by the Agents or by the Company, as the case may be, is hereinafter referred to as a &#8220;Permitted Free Writing
Prospectus.&#8221; The Company represents and warrants that it has treated and agrees that it will treat each Permitted Free Writing
Prospectus as an &#8220;issuer free writing prospectus,&#8221; as defined in Rule&nbsp;433, and has complied and will comply with the
requirements of Rule&nbsp;433 applicable to any Permitted Free Writing Prospectus, including timely filing with the Commission where
required, legending and record keeping. For the purposes of clarity, the parties hereto agree that all free writing prospectuses, if
any, listed in <U>Exhibit&nbsp;23</U> hereto are Permitted Free Writing Prospectuses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Absence
of Fiduciary Relationship</U>. The Company acknowledges and agrees that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
Agent is acting solely as agent in connection with the public offering of the Placement Shares and in connection with each transaction
contemplated by this Agreement and the process leading to such transactions, and no fiduciary or advisory relationship between the Company
or any of its respective affiliates, stockholders (or other equity holders), creditors or employees or any other party, on the one hand,
and the Agents, on the other hand, has been or will be created in respect of any of the transactions contemplated by this Agreement,
irrespective of whether or not any Agent has advised or is advising the Company on other matters, and the Agents have no obligation to
the Company with respect to the transactions contemplated by this Agreement except the obligations expressly set forth in this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;it
is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated
by this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Agents have not provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated by this Agreement
and it has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;it
is aware that the Agents and their affiliates are engaged in a broad range of transactions which may involve interests that differ from
those of the Company and such Agent have no obligation to disclose such interests and transactions to the Company by virtue of any fiduciary,
advisory or agency relationship or otherwise; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;it
waives, to the fullest extent permitted by law, any claims it may have against the Agents for breach of fiduciary duty or alleged breach
of fiduciary duty in connection with the sale of Placement Shares under this Agreement and agrees that the Agents shall not have any
liability (whether direct or indirect, in contract, tort or otherwise) to it in respect of such a fiduciary duty claim or to any person
asserting a fiduciary duty claim on its behalf or in right of it or the Company, employees or creditors of Company, other than in respect
of the Agents&#8217; obligations under this Agreement and to keep information provided by the Company to the Agents and their counsel
confidential to the extent not otherwise publicly-available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="color: #231f20"><U>Termination
of Prior Sales Agreement</U>. The Company and the Agents acknowledge and agree that the At Market Issuance Sales Agreement dated as of
December&nbsp;23, 2022 between the Company and B. Riley Securities,&nbsp;Inc. is hereby terminated.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Definitions</U>.
As used in this Agreement, the following terms have the respective meanings set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<U>Applicable
Time</U>&#8221; means (i)&nbsp;each Representation Date and (ii)&nbsp;the time of each sale of any Placement Shares pursuant to this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<U>Issuer
Free Writing Prospectus</U>&#8221; means any &#8220;issuer free writing prospectus,&#8221; as defined in Rule&nbsp;433, relating to the
Placement Shares that (1)&nbsp;is required to be filed with the Commission by the Company, (2)&nbsp;is a &#8220;road show&#8221; that
is a &#8220;written communication&#8221; within the meaning of Rule&nbsp;433(d)(8)(i)&nbsp;whether or not required to be filed with the
Commission, or (3)&nbsp;is exempt from filing pursuant to Rule&nbsp;433(d)(5)(i)&nbsp;because it contains a description of the Placement
Shares or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission
or, if not required to be filed, in the form retained in the Company&#8217;s records pursuant to Rule&nbsp;433(g)&nbsp;under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<U>Rule&nbsp;172</U>,&#8221;
 &#8220;<U>Rule&nbsp;405</U>,&#8221; &#8220;<U>Rule&nbsp;415</U>,&#8221; &#8220;<U>Rule&nbsp;424</U>,&#8221; &#8220;<U>Rule&nbsp;424(b)</U>,&#8221;
 &#8220;<U>Rule&nbsp;430B</U>,&#8221; and &#8220;<U>Rule&nbsp;433</U>&#8221; refer to such rules&nbsp;under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this Agreement to financial statements and schedules and other information that is &#8220;contained,&#8221; &#8220;included&#8221;
or &#8220;stated&#8221; in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to
mean and include all such financial statements and schedules and other information that is incorporated by reference in the Registration
Statement or the Prospectus, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing shall
be deemed to include the copy filed with the Commission pursuant to EDGAR; all references in this Agreement to any Issuer Free Writing
Prospectus (other than any Issuer Free Writing Prospectuses that, pursuant to Rule&nbsp;433, are not required to be filed with the Commission)
shall be deemed to include the copy thereof filed with the Commission pursuant to EDGAR; and all references in this Agreement to &#8220;supplements&#8221;
to the Prospectus shall include, without limitation, any supplements, &#8220;wrappers&#8221; or similar materials prepared in connection
with any offering, sale or private placement of any Placement Shares by the Agents outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Remainder
of the page&nbsp;intentionally left blank]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing correctly sets forth the understanding between the Company and each of the Agents, please so indicate in the space provided
below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and each of the Agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JOURNEY
    MEDICAL CORPORATION</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Claude Maraoui&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Claude Maraoui&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    President and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACCEPTED
    as of the date first-above written:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
    RILEY SECURITIES,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Chad Ritchie</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;Chad Ritchie</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Managing Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LAKE
    STREET CAPITAL MARKETS, LLC</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michael Townley</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;Michael Townley</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Head of Investment Banking</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
Page&nbsp;to At Market Issuance Sales Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULE
1</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 40%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORM&nbsp;OF
PLACEMENT NOTICE</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 40%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From:</FONT></TD>
  <TD>Journey Medical Corporation</TD></TR>

<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To:</FONT></TD>
  <TD>[B. Riley Securities,Inc.][Lake Street Capital Markets, LLC]</TD></TR>

<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
  <TD>[<FONT STYLE="font-family: Symbol">&middot;</FONT>]</TD></TR>

<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject:</FONT></TD>
  <TD>At Market Issuance--Placement Notice</TD></TR>

<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
  <TD>[<FONT STYLE="font-family: Symbol">&middot;</FONT>]</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms and subject to the conditions contained in the At Market Issuance Sales Agreement by and among Journey Medical Corporation,
a Delaware corporation (the &#8220;<U>Company</U>&#8221;), B. Riley Securities,&nbsp;Inc. and Lake Street Capital Markets, LLC, dated
August&nbsp;28, 2025, the Company hereby requests that [<I>identify Designated Agent</I>] sell up to [____] of the Company&#8217;s Common
Stock, par value $0.0001 per share, at a minimum market price of $&#9;&#8239;&#8239;&#8239;&#8239;&nbsp;per share, during the time period
beginning [month, day, time] and ending [month, day, time].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULE
2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>________________________</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>________________________</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall pay to the Designated Agent in cash, upon each sale of Placement Shares pursuant to this Agreement, an amount equal to
3.0% of the gross proceeds from each sale of Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULE
3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>________________________</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice
Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>________________________</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>The
Company</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ramsey Alloush</FONT></TD>
    <TD STYLE="width: 65%; text-align: justify">[***]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claude Maraoui</FONT></TD>
    <TD STYLE="text-align: justify">[***]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph Benesch</FONT></TD>
    <TD STYLE="text-align: justify">[***]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>B. Riley Securities</U></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keith Pompliano</FONT></TD>
    <TD>[***]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott Ammaturo</FONT></TD>
    <TD>[***]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a copy to [***]</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Lake Street Capital Markets, LLC</U></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Townley</FONT></TD>
    <TD>[***]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jon Miller</FONT></TD>
    <TD>[***]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alyssa Wallace</FONT></TD>
    <TD>[***]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Fenton</FONT></TD>
    <TD>[***]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jim Speight</FONT></TD>
    <TD>[***]</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT&nbsp;7(1)</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form&nbsp;of
Representation Date Certificate</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>___________,
20___</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Representation Date Certificate (this &#8220;<U>Certificate</U>&#8221;) is executed and delivered in connection with <U>Section&nbsp;7(1)</U>&nbsp;of
the At Market Issuance Sales Agreement (the &#8220;<U>Agreement</U>&#8221;), dated August&nbsp;28, 2025, and entered into by and among
Journey Medical Corporation (the &#8220;<U>Company</U>&#8221;), B. Riley Securities,&nbsp;Inc. and Lake Street Capital Markets, LLC.
All capitalized terms used but not defined herein shall have the meanings given to such terms in the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company hereby certifies as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
of the date of this Certificate (i)&nbsp;the Registration Statement does not contain any untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading and (ii)&nbsp;neither
the Registration Statement nor the Prospectus contain any untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made,
not misleading and (iii)&nbsp;no event has occurred as a result of which it is necessary to amend or supplement the Prospectus in order
to make the statements therein not untrue or misleading for this paragraph 1 to be true.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
of the representations and warranties of the Company contained in the Agreement were, when originally made, and are, as of the date of
this Certificate, true and correct in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as waived by the Agents in writing, each of the covenants required to be performed by the Company in the Agreement on or prior to the
date of the Agreement, this Representation Date, and each such other date prior to the date hereof as set forth in the Agreement, has
been duly, timely and fully performed in all material respects and each condition required to be complied with by the Company on or prior
to the date of the Agreement, this Representation Date, and each such other date prior to the date hereof as set forth in the Agreement
has been duly, timely and fully complied with in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subsequent
to the date of the most recent financial statements in the Prospectus, and except as described in the Prospectus, including Incorporated
Documents, there has been no Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
stop order suspending the effectiveness of the Registration Statement or of any part thereof has been issued, and no proceedings for
that purpose have been instituted or are pending or threatened by any securities or other governmental authority (including, without
limitation, the Commission).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
order suspending the effectiveness of the Registration Statement or the qualification or registration of the Placement Shares under the
securities or Blue Sky laws of any jurisdiction are in effect and no proceeding for such purpose is pending before, or threatened, to
the Company&#8217;s knowledge or in writing by, any securities or other governmental authority (including, without limitation, the Commission).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned has executed this Representation Date Certificate as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; background-color: White">JOURNEY MEDICAL CORPORATION</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White; width: 45%">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT&nbsp;23</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Permitted
Issuer Free Writing Prospectuses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[None].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 43; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>derm-20250828.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWayJ6bOdzZR+yYkxtmB6bdlqfy8kuDjWVi804pmmkWAK -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:DERM="http://journeymedicalcorp.com/20250828" elementFormDefault="qualified" targetNamespace="http://journeymedicalcorp.com/20250828">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://journeymedicalcorp.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="derm-20250828_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="derm-20250828_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>derm-20250828_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>derm-20250828_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="derm-20250828.xsd#Cover" roleURI="http://journeymedicalcorp.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://journeymedicalcorp.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2524202d2_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2524202d2_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !1 -8# 2(  A$! Q$!_\0
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M#\E K92<:>@NIY[\0?$7B*^\?6GA#0;]['>J*SJVTL[#=DL.<!?3WJW#X?\
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MHOB+X<^%7\.W_DZ-;031V\CQRQ JRL%)!SGGD=Z\DT[Q!>I\%M6L#,QC%]'
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M0Z:GQ6L=4U:,SZ%?QQ2&1"=KIMVG!7KC /'8BNK70O@^ZAA<Z8 1GG4&!_\
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144 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 28, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 28,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Journey Medical Corporation<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001867066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-1879539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9237 E Via de Ventura Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Scottsdale<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">AZ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">85258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">434-6670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DERM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2524202d2_8kseq1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://journeymedicalcorp.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>derm-20250828.xsd</File>
    <File>derm-20250828_lab.xml</File>
    <File>derm-20250828_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2524202d2_8kseq1.htm">tm2524202d2_8kseq1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2524202d2_8kseq1.htm": {
   "nsprefix": "DERM",
   "nsuri": "http://journeymedicalcorp.com/20250828",
   "dts": {
    "schema": {
     "local": [
      "derm-20250828.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "derm-20250828_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "derm-20250828_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2524202d2_8kseq1.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://journeymedicalcorp.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-08-28",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2524202d2_8kseq1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-08-28",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2524202d2_8kseq1.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-25-084879-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-084879-xbrl.zip
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MZ%0O1?4*T$H](U96@7Y7E:"\%MOOE]<W7<M/<K/>)/]:X93(+?\%4$L#!!0
M   ( ,*+'%NTIZ"58@<  .A7   5    9&5R;2TR,#(U,#@R.%]P<F4N>&UL
MS9Q-<]LV$(;OG>E_8-6S+$MNTUBQF[$5*Z.)$[N6D[2]9" 2DE"#@ 8 +>G?
M%R!%11\$N+YPXX,M4PMPWV=!@$L O'B[2GGT3)5F4ERVNB>GK8B*6"9,S"Y;
MG\?MJ_%@-&I%VA"1$"X%O6P)V7K[Y\\_1?;GXI=V.QHRRI-^]$[&[9&8RC?1
M)Y+2?O2>"JJ(D>I-](7PS!V10\:IB@8R77!JJ/VB.'$_>G72G43M-J#:+U0D
M4GU^&&VKG1NST/U.9[E<G@CY3)92/>F36*:P"L>&F$QO:SM=G6Y^BN(7G(FG
MOOLU(9I&%I?0_95FERUWWLUIEV<G4LTZO=/3;N?OC[?C>$Y3TF;"88MIJRSE
M:JDJUST_/^_DWY:F1Y:KB>+E.<XZI3O;FNVW+&"_XXEF?9V[=RMC8O*HUYXF
M\EJX_]JE6=L=:G=[[;/NR4HGK1)^3E!)3A_H-,IE]LUZ85N29JXAM#;'YHI.
M+UL)5:FMJ/?[Z>O>:U?-KP-IVV<K<A78L&_=_4]F2M!U2A,6$QY+M7 Q[SBS
MSJ9(9\^#A:*:"I.+OK4']ERA*V,;%DU*9UPU+SG5IBYF7+%- ^I&;=?:LM2>
MU7XL+#<NE4YQ&>_YP5U4I-IG4K;PG+VF\<E,/G<2RCJ.D_N0 \MAV7^^Y2>Z
MFFBC2&S*FCB94)[7_\W:')AT&O"J)/%H:ZQV:M_BT*?=\%VI.)+*-A7+NJR+
MJ'@O:,>-=6/161!E*VK'<\:W\9XJF?KH;$A(CZ.[H.PIFJ%Y9<^?.!^&G,RJ
M<1Z8 'EV,8!6JL$B^H[J6+&%XU(#=L\2R+>'RK="6\.8RVOG@<Z8\]>YXH9@
MZ@Z&^P5/$2#X,\R>(J@6*0)70F2$/]"%5#7@]RV!O'_#Y%VE#0GS7QE1ABJ^
MAI ^,@;"_AT3MD<A$N]'181FC@\$^+$UD/@KU!L/CT8DY.,YY=QE=42 6GF5
M/1#['YC8_3I_ / WSVY\MT,+G/U.$2#^US\*_B.U2!&XIXK)Q [I"L#^R!A(
M_1R3ND<A*N\;D4!I;TW!^0\^[ -Y2*B'3,>$%QX-[3$=QEUA#D6.DG/6RD3%
M_@\E"@Q]QQB*'"4-K9'8,/!!IM2>,\%>Q6\-18Z2@-:);)CYC3#,K-TTP*<L
MG7Q_<+K/^M@*RA@EZ?2)0F%;/FD0QDUOA/@>6D(9H^2:(7$HG =6CR)\)!*Z
M^D#7(=!'IE#2*#EF4!X*ZGO%4J+68Q;7=QK'ME#8*)EE6" *[4>R&B56%9NR
M8H*P'KJW")0]2EH)DHL2@I%P<XQRYW'Q0&;V>EP/9!+LTFL*0L.!DF^^0#I*
M4*Z2Q.+2FS^W3-!N*!25YN Y(KP !&3^(-A[+\/>@V-'R4-K9?X@V,]>AOT,
MCATE%ZV5B8E]8#_>J4>Y],Q >XVAR%%RT1J)F,#SD>9.W2OYS(IU4G74CTI
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M1JW/[<''_NF'X=EI@71+G1*1I7IM1R#PV)77EPIM9)/1_+PN/GKAAUN_3L>
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M;=/-_@39HV><PC#@\*8Y'O4F:D"2%U4-Q_$TJ[,<5BEO8=DOHAP&G?&WLZ*
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MQ3FAA2FQ#&H*%TT49%F5!Z@A[?%>9@D-1_,Z>\I BDQ8F.1P=S+7IJQA0AH
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M&DGX(D6_EOK:5AX?+9:OJ:0N:0'E%YP&X3O.U%/W\5$9A:N7I</;"TMHZ0/
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M*=)#Y+WS:LEMJ+1='P<;7:&-]KO#YKB[.^"88;A\7:0QK;"Y[L;@14-ZZIL
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MIHH-75W.1)1V*ZJW(:IU_;40%'2^WX"H6:7S5NO)J?D:U9&";+S$UM;_0,F
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M50$AM%.M:9^D]+=>O;X8U7T7L>O=<AD:KO*M (1DN02$7\ ^Q8'/>K3[GI_
M8=$,78R<UQ%]$CL]8Q%6&(XG*IB ^V;TT1(+/.7NN;#[;2>=3/1M\CLD?<L6
M";Z#C S]&E$WPF]9@PU'0_/&*BF)36*/N28/(GXY=@3BZ"%7SH'RFG&:3+0
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MF_]*3V]A9<FKE.U)2LU@H$"+7VWL@0RS7KJ%XC&#7BEJ$H2UKI-D "9*AZ9
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MDC)TO?PJ1D Z+8*2Q1Z%' ?BJ W"S%I3/>&JNM0R^[K27'BX6?G):<NN/ZH
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M*PNWY$COZ&Z@A%I\W\&?YWWV[@E A)%]]K55+&B>IY#</3LO2CC&(@)9!FG
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M[C>/3]M.JWUZ>MD\.>F<O_N??^S_@W[O739;ZO?/GH5$,[PXBMQI"C2HG][
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M#1I44SSN40*WZYBO=+D.[9X.KKZ#0EBB9$9C!7\'WDQZ-)4U*.*;<,_IL ;
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M::&X'U(_P>UTL3ZN3[M1KQWN;ZT[^XE2*,+T7M['C.8PM5.:[7-ATIJQZWQ
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MND>Z+![^W/QP?''R\5?\X7W_[/37_P]02P,$%     @ PHL<6],Z(")B"P
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M?^UP[U$FWZ>_,G!_=D!_G? ?4$L! A0#%     @ PHL<6]6PG6DR P    P
M !$              ( !     &1E<FTM,C R-3 X,C@N>'-D4$L! A0#%
M  @ PHL<6WRC3L#]"@  ?X8  !4              ( !80,  &1E<FTM,C R
M-3 X,CA?;&%B+GAM;%!+ 0(4 Q0    ( ,*+'%NTIZ"58@<  .A7   5
M          "  9$.  !D97)M+3(P,C4P.#(X7W!R92YX;6Q02P$"% ,4
M" #"BQQ;_@/\\4 8   '@0  %@              @ $F%@  =&TR-3(T,C R
M9#)?.&MS97$Q+FAT;5!+ 0(4 Q0    ( ,*+'%O%Q7FHM+   /J&!  6
M          "  9HN  !T;3(U,C0R,#)D,E]E>#$P+3$N:'1M4$L! A0#%
M  @ PHL<6],Z(")B"P  I#   !4              ( !@M\  '1M,C4R-#(P
C,F0R7V5X-2TQ+FAT;5!+!08     !@ & ) !   7ZP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tm2524202d2_8kseq1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="derm-20250828.xsd" xlink:type="simple"/>
    <context id="AsOf2025-08-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001867066</identifier>
        </entity>
        <period>
            <startDate>2025-08-28</startDate>
            <endDate>2025-08-28</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-08-28" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-08-28" id="Fact000004">0001867066</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-08-28" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-08-28" id="Fact000010">2025-08-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-08-28" id="Fact000011">Journey Medical Corporation</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-08-28" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-08-28" id="Fact000013">001-41063</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-08-28" id="Fact000014">47-1879539</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-08-28" id="Fact000015">9237 E Via de Ventura Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-08-28" id="Fact000016">Suite 105</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-08-28" id="Fact000017">Scottsdale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-08-28" id="Fact000018">AZ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-08-28" id="Fact000019">85258</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-08-28" id="Fact000020">480</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-08-28" id="Fact000021">434-6670</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-08-28" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-08-28" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-08-28" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-08-28" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-08-28" id="Fact000026">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-08-28" id="Fact000027">DERM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-08-28" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-08-28" id="Fact000029">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2025-08-28" id="Fact000030">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
